Hepatitis B, Hepatitis C and HIV in Irish prisoners: prevalence and risk. by Allwright, Shane et al.
HEPATITIS B, HEPATITIS C AND HIV 
IN IRISH PRISONERS: 
PREVALENCE AND RISK 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Report prepared for the Minister for Justice, Equality and Law Reform 
by 
the Department of Community Health and General Practice, 
Trinity College, Dublin 
 
 
 
 
 
 
BAILE ÁTHA CLIATH 
ARNA FHOILSIÚ AG OIFIG AN tSOLATHAIR 
Le ceannach díreach ón 
OIFIG DHIOLTA FOILSEACHÁIN RIALTAIS, 
TEACH SUN ALLIANCE, SRAID THEACH LAIGHEAN, BAILE ATHA CLIATH 2, 
Nó tríd an bpost ó 
FOILSEACHÁIN RIALTAIS, AN RANNOG POST-TRÁCHTA, 
4 – 5 BÓTHAR FHEARCHAIR, BAILE ÁTHA CLIATH 2, 
(Tell: 01-6476834 nó 01 – 6476835; Fax: 01 – 4752760 
nó trí aon díoltóir leabhar. 
________ 
 
DUBLIN 
PUBLISHED BY THE STATIONERY OFFICE 
To be purchased directly from the 
GOVERNMENT PUBLICATIONS SALE OFFICE, 
SUN ALLIANCE HOUSE, MOLESWORTH STREET, DUBLIN 2 
or by mail order from 
GOVERNMENT PUBLICATIONS, POSTAL TRADE SECTION, 
4 – 5 HARCOURT ROAD, DUBLIN 2, 
(Tel: 01 – 6476834 or 01 – 6476835; Fax: 01 – 4752760 
or through any bookseller. 
________ 
 
£7.00  €8.89 
 Acknowledgements 
The authors thank the staff of the Department of Justice, Equality and Law Reform, the gov-
ernors and staff of all the prisons visited and especially the prisoners who participated in this 
study. We also thank our colleagues who helped with the fieldwork. Special thanks is due to 
the research team at the Public Health Laboratory Service, London, for their generous support 
and sharing of information, and we would like to acknowledge the expertise of John Parry 
who analysed and interpreted our laboratory specimens. Thank to all the members of the De-
partment of Community Health and General Practice for their support, in particular Alan 
Kelly for his statistical advice, Kornelius Elstner for the layout of the document and espe-
cially Ailbhe Mealy for administrative support. 
Dr Shane Allwright1 
Dr Joseph Barry, 1,2 
Dr Fiona Bradley1 
Ms Jean Long1 
Dr Lelia Thornton2 
 
 
                                                        
1 Department of Community Health and General Practice, Trinity College Dublin 
2 Department of Public Health, Eastern Health Board, Dr. Steevens’ Hospital 
Table of Contents 
Page No. 
List of tables ........................................................................................................................ iii 
List of figures ........................................................................................................................v 
List of abbreviations............................................................................................................ vii 
Glossary of terms...................................................................................................................ix 
Summary ...............................................................................................................................1 
1 - Introduction.......................................................................................................................2 
1.1 Hepatitis B, hepatitis C and HIV in Ireland .........................................................2 
1.2 Prisons in Ireland .................................................................................................2 
1.3 Hepatitis B, hepatitis C and HIV in prisons elsewhere........................................3 
1.4 Use of oral fluid ...................................................................................................3 
1.5 Drug policy in Ireland..........................................................................................3 
1.6 Rationale for the study.........................................................................................3 
1.7 Aim and objectives ..............................................................................................4 
2 - Methods .............................................................................................................................5 
2.1 Sampling..............................................................................................................5 
2.2 Fieldwork.............................................................................................................5 
2.3 Data collection instruments .................................................................................6 
2.4 Collection of oral fluid specimens .......................................................................6 
2.5 Explanation of laboratory tests used....................................................................7 
2.6 Comments and observations ................................................................................7 
2.7 Statistical methods ...............................................................................................7 
3 – Results ...............................................................................................................................8 
3.1 General information.............................................................................................8 
3.2 Prevalence of hepatitis B, hepatitis C and HIV .................................................10 
3.3 Uptake of hepatitis B vaccine ............................................................................14 
3.4 Drug use.............................................................................................................16 
3.5 Sexual practices .................................................................................................20 
3.6 Risk Factors for infection ..................................................................................22 
3.7 Comments and observations ..............................................................................25 
4 - Discussion ........................................................................................................................29 
4.1 Environment of prisons......................................................................................29 
4.2 Infections within prison .....................................................................................29 
4.3 Hepatitis B vaccination......................................................................................30 
4.4 Drug use in prison..............................................................................................30 
4.5 Young prisoners .................................................................................................30 
4.6 Sexual risk factors..............................................................................................30 
4.7 Prison health service ..........................................................................................30 
4.8 Oral fluid ..........................................................................................................31 
5 - Recommendations...........................................................................................................32 
5.1 Topic–specific recommendations.......................................................................32 
5.2 Organisational recommendations.......................................................................33 
References .............................................................................................................................35 
Appendices 
 
 
 
i 

List of Tables 
Table 1 Response rate by prison ........................................................................................ 8 
Table 2a Prevalence of hepatitis B and C and HIV by prison category............................. 10 
Table 2b Prevalence of hepatitis B and C and HIV by injecting drug use..........................11 
Table 2c Prevalence of hepatitis B and C and HIV by age.................................................11 
Table 2d Prevalence of hepatitis B and C and HIV by gender ...........................................11 
Table 3 Comparison of proportions positive for oral fluid test with self reported 
status, as a percentage of the total survey population and as a percentage of 
those previously tested........................................................................................ 12 
Table 4a Self reported hepatitis B status and the oral fluid test results ............................. 13 
Table 4b Self reported hepatitis C status and the oral fluid test results ............................. 13 
Table 4c Self reported HIV status and the oral fluid test results ....................................... 13 
Table 5 Self reported hepatitis B vaccine coverage in each prison.................................. 14 
Table 6a Hepatitis B vaccination coverage by time spent in prison in the last 10 
years ................................................................................................................ 15 
Table 6b Hepatitis B vaccination coverage by injecting drug use ..................................... 15 
Table 6c Hepatitis B vaccination coverage by hepatitis B status ...................................... 15 
Table 7 Proportion of respondents who smoked heroin or ever injected drugs by 
prison category.................................................................................................... 16 
Table 8 Proportion of respondents who smoked heroin or ever injected drugs by 
gender ................................................................................................................ 17 
Table 9 Number (%) on methadone at committal by length of time spent in prison 
on this sentence................................................................................................... 19 
Table 10 Reported sexual risk factors................................................................................ 20 
Table 11 Reported sexual risk factors for hepatitis B........................................................ 21 
Table 12 Reported sexual risk factors for hepatitis C........................................................ 21 
Table 13 Reported sexual risk factors for HIV.................................................................. 21 
Table 14a Logistic regression model to identify determinants of hepatitis B infection ...... 22 
Table 14b Logistic regression model to identify determinants of hepatitis C infection ...... 23 
Table 14c Logistic regression model to identify determinants of HIV infection ................ 23 
 
 
iii 

List of figures 
Figure 1 Age profile of prison population and survey respondents .................................... 9 
Figure 2 Prison history of respondents................................................................................ 9 
Figure 3    Number (%) of respondents oral fluid test positive for hepatitis B and C  
                    and HIV and the overlap between the infections, N = 1193 (100%)                12 
Figure 4 Inter-relationship between smoking heroin and injecting drug use 
N = 1179 (100%) ................................................................................................ 16 
Figure 5 Age started injecting drugs ................................................................................. 17 
Figure 6 Last time drug users injected before committal to prison................................... 17 
Figure 7 Frequency of injecting in the month prior to the survey among injecting 
 drug users resident in prison for more than 3 months on this sentence .............. 18 
Figure 8  Frequency of sharing injecting equipment in the month before 
 committal versus sharing in prison ..................................................................... 18 
 
 
v 

List of Abbreviations 
CI  Confidence interval 
df  Degrees of freedom 
EIA  Enzyme immunoassay 
GP  General practitioner 
HBc  Hepatitis B virus core antigen 
HBV  Hepatitis B virus 
HCV  Hepatitis C virus 
HIV  Human immunodeficiency virus 
IDU  Injecting drug use/user 
RIA  Radio-immune assays 
TB  Tuberculosis 
 
 
vii 

Glossary of Terms 
A cross sectional survey is a descriptive (epidemiological) study in which the status of a 
group of individuals is assessed at a point in time, with respect to the presence or absence of 
both the exposure(s) and disease(s) of interest. 
Prevalence estimates the proportion of the population that have a disease at a specific point or 
period in time. 
Random sampling is a technique used to select the survey sample from the total population of 
interest by which every member has an equal chance of being selected. 
A confidence interval is the range of values in which the true value of a parameter (e.g. pro-
portion) is likely to be found. By convention a 95% confidence interval is usually calculated 
i.e. the range that will include the true value 95% of the time. 
A p-value is a probability value which measures the likelihood that an observed result oc-
curred due to chance alone. Probability is measured between the range 0-1. by convention a 
value of p <0.05 is considered statistically significant (for health related studies). 
X2 test is a statistical test to determine if there is a statistically significant association between 
two grouped variables. 
Multiple logistic regression analysis is a statistical technique employed to estimate the level 
of association between one or more variables and a binary outcome of interest while control-
ling for a number of confounding factors (other factors independently associated with both 
the exposure and the outcome). The odds ratio is used to measure the association. 
The odds ratio calculates the ratio of the odds of exposure among the cases (those with the 
disease) to that among the controls (those without the disease). An odds ratio of 1 implies the 
same experience among the cases and the controls. An odds ratio less than 1 implies the ex-
posure is protective and an odds ratio greater than 1 implies those exposed have a higher risk 
of contracting the disease. 
A cohort is a group of individuals with a similar time linked exposure/experience. 
Response rate is the proportion of the selected sample who take part in a study. 
IgG is a test which ensures that the specimen is of adequate quality for analysis. 
RIBA is a confirmatory test for hepatitis C. 
 
 
 
ix 

 
…………………………………………………………………………………..……………………………….. 
 
 
Summary 
A cross sectional survey of hepatitis B, hepatitis C and HIV prevalence in the Irish prisoner 
population was undertaken. The study was carried out in nine prisons, five of which had been 
classified as high risk and four as medium risk for infection. All the high risk prisons were in 
Dublin while the medium risk prisons were outside Dublin. Overall there was excellent co-
operation with the survey; the response rate was 88%. A total of 1,205 prisoners took part in 
the survey, which consisted of completing a four page questionnaire and collecting a sample 
of oral fluid for testing for antibodies to hepatitis B, hepatitis C and HIV. The fieldwork for 
the study was carried out between September and November 1998. 
Overall the prevalence of infection with hepatitis B among prisoners was 9%, the prevalence 
of infection with hepatitis C was 37% and the prevalence of HIV was 2%. Infection rates in 
women prisoners were slightly, but not significantly, higher: prevalence of hepatitis B was 
12%, hepatitis C prevalence was 42% and HIV prevalence 2%. All infection rates were con-
siderably higher in the high risk prisons and, not unexpectedly, among drug users (where the 
prevalence of hepatitis B was 19%, hepatitis C was 81% and HIV was 4%).  Hepatitis B 
prevalence was higher in those over 30 whereas hepatitis C rates were higher in those under 
30; 38.5% of all prisoners had evidence of at least one of these three infections. 
Only 29% had completed the three dose course of hepatitis B vaccination although a further 
19% had received one or two doses. 
Six hundred and thirty respondents (52%) reported opiate use and 514 (43%) reported ever 
injecting drugs. The percentage reporting ever injecting drugs was 21% in the medium risk 
prisons and 58% in the high risk prisons. 60% of women prisoners reported injecting drug 
use. 21% of injectors first started injecting in prison. Just over one third (37%) had shared 
drug injecting equipment (needles, syringes, spoons and filters) before committal to prison. 
Of those who injected in prison, 58% had shared drug injecting equipment (all types). Almost 
half (45%) of injecting drug users who had been in prison for three months or more said they 
had injected drugs in the preceding month, and, of these, one third had injected more than 20 
times. 
One in 40 (28/1116) men reported ever having anal sex with another man and just under 2% 
(20/1087) reported having anal sex with men in prison. 
Multivariate logistic regression analyses showed that injecting drug use was by far the most 
important predictor for both hepatitis B and hepatitis C infection. Prevalence of hepatitis C 
was higher in younger prisoners and the risk of infection was higher in those who had spent 
longer in prison and, among injecting drug users, in those who shared injecting equipment. 
Although injecting drug use was associated with increased risk for all three infections, for 
HIV and hepatitis B, sexual practices were also important. Anal sex was the strongest predic-
tor of HIV although the numbers involved were very small. A history of treatment for sexu-
ally transmitted infections was linked to increased risk of both HIV and hepatitis B. 
The frequency of drug using practices and prevalence of the three infections were all signifi-
cantly greater in the Dublin prisons. Numerically, hepatitis C was by far the most important 
of three infections. The fact that hepatitis C was commoner in younger prisoners implies 
health problems of major proportions in the next ten to twenty years. Clearly the survey find-
ings raise serious questions about how best to manage the current and future health and safety 
of both prisoners and staff.  
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1 - Introduction 
1.1 Hepatitis B, hepatitis C and HIV in Ireland 
Detailed epidemiological data are not available for hepatitis B infection in the Irish popula-
tion as a whole. In Ireland the prevalence of hepatitis B is low among the general population, 
about 1 in 4,000 among new blood donors and 1 in 3,000 women attending for antenatal 
care.1 Data from specific sub-groups show a high prevalence of hepatitis B markers (68% and 
50%) in persons with intellectual disability living in residential accommodation2,3 and a 
prevalence of 11% in intellectually disabled persons not living in residential accommodation.4 
In a cohort of injectors attending Eastern Health Board methadone clinics the prevalence of 
anti-hepatitis B core antibody, based on laboratory reports, was 29% (Dr. J. Barry, personal 
communication, 1995). 
Hepatitis C in Ireland mainly occurs in two populations: cohorts of individuals who became 
infected through anti D or other infected blood products, and injecting drug users. Among 
injecting drug users the prevalence varied between 52%5 and 76% (Dr. J. Barry, personal 
communication, 1995). 
The rate of HIV infection in antenatal women is 0.02%.6 Voluntary linked testing for antibod-
ies to HIV has been available in Ireland since 1985 and, up to the end of 1998, there had been 
1,986 persons identified as having antibodies to HIV.7 Of these, 844 (42%) were intravenous 
drug users and 458 (23%) were homosexual men. In the cohort of injectors attending Eastern 
Health Board methadone clinics in 1997, the prevalence of HIV, based on laboratory reports, 
was 8% (Dr. J. Barry, personal communication, 1995). 
From the above one can deduce that all three viruses are more prevalent in drug users than in 
the general population and, among drug users, hepatitis C is the most common. 
1.2 Prisons in Ireland 
In 1993 the Department of Justice published the Report of the Advisory Committee on Com-
municable Diseases in Prison.8 Neither hepatitis B nor hepatitis C were mentioned in the re-
port and, in relation to HIV, the report stated that ‘current policy may militate against a pris-
oner seeking advice about their HIV status when in prison’. In February 1996, the Department 
of Justice estimated that 40% of prisoners had a history of serious drug misuse.9 At that time 
the total prison population was just over 2,000. Since 1993 there has not been a published 
report on policy in relation to infection control in prison. With regard to hepatitis B vaccine, a 
written policy has been circulated to prison medical staff and the policy is to offer vaccination 
to those with sentences longer than eight months (Dr. E. Dooley, personal communication, 
1995). In order to maximise protection against hepatitis B, three doses are required at zero, 
one and six months. 
In March 1999, the Department of Justice, Equality and Law Reform circulated a draft action 
plan entitled Drug Misuse and Drug Treatment in the Prison System.10 The action plan advo-
cates that services available outside prison to injecting drug users should be available within 
prison where at all possible. The Department of Justice has not published any systematic in-
formation on prevalence of hepatitis B, hepatitis C, or HIV among the prisoner population. 
“Prisoner” is a named category in the voluntary linked HIV testing system and, since 1985, 
26 individuals with such a designation have tested positive.7 This is not a reliable indicator of 
prevalence of the virus among prisoners. 
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1.3 Hepatitis B, hepatitis C and HIV in prisons elsewhere 
The reported prevalence of HIV in prisons in western Europe is generally low, 0-2%,11,12,13 
although one French prison reported HIV prevalence of 6%.14 The prevalence of hepatitis B 
and C in prisons has been less frequently reported. Two studies carried out in Australia and 
Greece reported a high prevalence of hepatitis C (39%, and 58% respectively).15,16 The study 
in Greece also indicated that 81% of its injecting drug users had hepatitis C; in the same study 
the prevalence of hepatitis B was 58% among the prison population and 63% among those 
injecting drugs.16 Several studies have also examined practices that may increase the risk of 
contracting these infections. Injecting drug use was the most common risk factor for hepatitis 
B, hepatitis C and HIV.16,17,18 Studies also reveal that those who share equipment, particularly 
needless or syringes, were most at risk.16,18,19 Individuals injecting for more than six years 
were also more likely to develop hepatitis C.16 Two studies found that those who had spent 
more time in prison were more likely to have contracted hepatitis C.16,20 Hepatitis B was as-
sociated with a high incidence of sharing injecting equipment and male homosexual inter-
course.14 
1.4 Use of oral fluid 
Traditionally, prevalence of hepatitis B, hepatitis C and HIV has been estimated by taking 
blood from subjects and carrying out a range of serological tests. Recently, techniques have 
been developed to allow for oral fluid analysis. This is a more convenient and safer body fluid 
on which to carry out virological tests and results obtained are comparable to those obtained 
with blood tests. 
1.5 Drug policy in Ireland 
In Ireland a larger proportion of individuals with HIV infection acquired their infection 
through injecting drug use than in other northern European countries.21 In 1991 the Depart-
ment of Health published a Government Strategy to Prevent Drug Misuse.22 This strategy rep-
resented a major policy shift in that it introduced a harm reduction approach, including the 
provision of methadone maintenance and needle exchange for injecting drug users on a wide 
scale. This policy was endorsed in 1992 in the Report of the National AIDS Strategy Commit-
tee.23 There are currently just under 4,000 individuals addicted to opiates who are on metha-
done replacement therapy (Dr. J. Barry, personal communication, 1999) and over 6,000 indi-
viduals have presented for needle exchange in the Dublin area since the service began in 
1989.24 Government policy in relation to drugs was reviewed and in 1996 the Report of the 
Ministerial Task Force on Measures to Reduce the Demand for Drugs recommended that spe-
cific attention be paid to prisons in the response to the drug issue.25 It was estimated at that 
time that approximately 70% of prisoners in Mountjoy prison had a history of drug misuse. 
There has been one attempt to measure the prevalence of opiate use in Ireland. This was a 
capture-recapture estimate, based on three 1996 data sets: methadone treatment list, acute 
hospital discharges and police data.26 The analysis was confined to Dublin residents and the 
estimated total number of opiate users was 13,460 (95% confidence interval 12,037 – 
15,306), a prevalence of 21 per 1,000 aged 15 – 54.  The wide confidence interval occurred 
because there was little overlap between the data sets.  Also, it was not clear whether the po-
lice data represented habitual opiate users. 
1.6 Rationale for the study 
It is against this background that the Department of Justice, Equality and Law Reform com-
missioned a study of the prevalence of hepatitis B, hepatitis C and HIV in Irish prisoners. The 
Department of Community Health & General Practice, Trinity College Dublin, was awarded 
the contract to undertake the study. The terms of reference in the Request for Proposal are 
given in Appendix 1.The study was designed in two phases: a census survey of 1,200 prison-
ers and a survey of 600 committal prisoners. The results of the census survey are presented in 
this report. 
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1.7 Aim and objectives 
The overall aim of the survey was to determine the prevalence of hepatitis B, hepatitis C and 
HIV in the Irish prisoner population, and to examine the association between the prevalence 
of these infections and factors such as age, prison history and risk behaviour, in particular 
injecting drug use, with a view to minimising transmission of hepatitis B, hepatitis C and HIV 
in Irish prisons. 
The objectives were to: 
• measure the prevalence of 3 blood borne viral infections: hepatitis B, hepatitis C and 
HIV in high and medium risk Irish prisons. 
• determine the extent of self reported risk behaviours in prisoners, both before and dur-
ing current sentence. 
• measure the association between risk behaviour, in particular injecting drug use, and 
prevalence. 
• compare self-reported prevalence of hepatitis B, hepatitis C and HIV with actual preva-
lence. 
• estimate the extent of hepatitis B immunisation in the prisoner population. 
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2 - Methods 
2.1 Sampling 
The prison population in Ireland at the time of the survey numbered approximately 2,700, 
located in 15 prisons. A sampling strategy was devised which allowed conclusions to be 
drawn about infection rates in groups of similar prisons by categorising the 15 prisons accord-
ing to expected prevalence rates for infection as high, medium or low. The decision to group 
the prisons in this way assured both confidentiality and an adequate sample for accurate esti-
mation of infection prevalence. 
The three low risk prisons (Curragh, Castlerea and Arbour Hill) were excluded as the number 
of prisoners involved (approximately 275) was inadequate to allow for a stable estimation of 
prevalence. For the purpose of sample size calculation, the predicted prevalence of infection, 
in particular hepatitis C, was estimated using information obtained from a study of drug users 
attending Health Board run clinics (Dr. J. Barry, personal communication, 1995), together 
with information from the Department of Justice, Equality and Law Reform on the estimated 
prevalence of intravenous drug use in prisons. It was estimated that a sample size of 1,200 
was required.27 Nine prisons were selected for survey: all the high risk prisons and a random 
sample (proportional to population size) of the medium risk prisons. The high risk prisons 
were Mountjoy Male, Mountjoy Female, St Patrick’s Institution, Wheatfield and the Training 
Unit, and the medium risk prisons were Cork, Limerick, Portlaoise and Shelton Abbey.∗ Fol-
lowing discussion with the Department of Justice, Equality and Law Reform and with repre-
sentatives of political prisoners, it was agreed that political prisoners would not form part of 
the study population. 
A census of all prisoners on a given day was carried out in the medium risk prisons and the 
two small high risk prisons, while in the three larger high risk prisons half of the population 
was sampled. Prisoners who were absent from the premises at the time of the survey, and the 
very small number of prisoners who were considered by the prison governor to be a safety 
risk for the research staff, were excluded from the sample. 
The survey was carried out over a three month period from September to November 1998. 
The fieldwork took between one and two days to complete in each prison. 
2.2 Fieldwork 
Preparatory work was carried out in each prison through meetings between the research team 
and the prison governor and key staff. The approach taken in carrying out the survey varied in 
different prisons according to the conditions and population of the individual prison. Staff and 
prisoners were briefed in advance of the survey by posters on notice boards, and by individual 
information leaflets. 
The survey was carried out by a team of researchers who met the prisoners in groups. The 
groups varied in size from 10 to 40. The survey team was briefed in advance and consisted of 
health professionals and non-professional researchers (see Appendix 2). A health professional 
was available at all times to answer questions of a medical nature. The prisoners were given 
an introductory talk lasting five to ten minutes explaining the purpose and process of the sur-
vey. They were advised that all data collected would be anonymous and confidential and that 
no 
                                                        
∗ The medium risk prisons not selected were: Fort Mitchell, Loughan House and Shanganagh Castle 
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 information that could identify an individual would be released to the prison authorities or to 
the Department of Justice, Equality and Law Reform. Prisoners were informed that they 
would not be able to get their individual test results from the survey, but were advised that 
testing was available through the prison medical service. They were invited to ask questions 
or make comments. With the agreement of the prisoners, the survey then proceeded. 
Prisoners who did not wish to meet the researchers in a group setting were approached indi-
vidually to explain the study to them and to seek their co-operation. In many cases this ap-
proach was successful and the survey was then carried out, usually in their cell. Those who 
did not wish to provide an oral fluid sample were asked to complete a questionnaire and some 
did so. The survey was voluntary. All eligible prisoners were encouraged to participate but no 
inducements were offered and no negative sanctions were imposed on non-respondents. 
2.3 Data collection instruments 
There were two parts to the survey: collection of an oral fluid specimen and completion of a 
questionnaire (Appendices 3a and 3b). In order to complete the process as quickly as possible, 
the questionnaire was generally filled in while the oral fluid specimen was being collected. 
The questionnaire was developed from that used by the Public Health Laboratory Service 
team in England and Wales and consisted of closed, multiple choice questions relating to de-
mography, details of prison sentence, history of injecting drug use, sexual practices, self-
reported HIV and hepatitis testing and results, and hepatitis B vaccination history. The ques-
tionnaire was self-administered and took an average of 5 minutes to complete. Those who had 
literacy difficulties were assisted in completing the questionnaire by a researcher. The survey 
was anonymous – no name, address or other identifier was recorded on either the question-
naire or the oral fluid specimen. Once completed, the questionnaire and oral fluid specimen 
were placed in an envelope by the respondent and all envelopes were then placed in a collec-
tion bag. A number was later assigned to each questionnaire and specimen, linking the two. 
At the end of each day of fieldwork the questionnaires were checked for internal consistency. 
On the survey day, anonymous demographic information was gathered on the entire prison 
population in each prison to calculate response rate and establish representativeness of re-
spondents. 
The survey procedures, including the use of the questionnaire and the oral fluid testing, were 
piloted on a group of prisoners and appropriate alternations were made following this experi-
ence. 
2.4 Collection of oral fluid specimens 
Oral fluid specimens were collected with a proprietary device called EpiScreen™ (Epitope 
Inc., Oregon, USA). It consists of a cotton fibre pad treated with a hypertonic salt solution on 
a plastic stick. Capillaries lining the gum and cheek mucosae leak significant amounts of 
plasma proteins, including immunoglobulins, into the mouth. The EpiScreen™ pad is de-
signed to collect oral fluid specimens rich in this capillary transudate (‘oral mucosal transu-
date’). The pad is placed between the lower gum and cheek and held in place for at least two 
minutes. After collection, the pad is placed in a tube, provided as part of the collection kit, 
containing a non-toxic preservative solution that inhibits bacterial growth and degradation of 
immunoglobulins. Once specimens are collected they can be stored for up to 21 days at tem-
peratures between 4 °C and 37 °C. For this study, specimens were kept refrigerated until 
transported in several large batches by overnight courier to the Central Public Health Labora-
tory in the United Kingdom. Laboratory processing of the specimens commenced on the next 
working day and the specimens were tested blind to demographic and risk factor characteris-
tics. The laboratory techniques used by the Central Public Health Laboratory are described in 
Appendix 4. 
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2.5 Explanation of laboratory tests used 
The laboratory test used on the oral fluid specimens was different for each of the three viruses 
examined. Knowledge of what each test implies is necessary to interpret the test results and a 
brief description of each test is given here. 
The hepatitis B antibody test used in this survey measures antibodies to the hepatitis B core 
antigen. This is a measure of ever having been infected ‘naturally’ with the hepatitis B virus. 
Best available evidence is that the long term carrier rate, and hence infectivity of someone 
who has ever been infected with hepatitis B is 10%28. The anti hepatitis core test in this sur-
vey has a sensitivity of 82% (18% false negative) and specificity greater than 99% (les than 
1% false positive). 
For hepatitis C, the Central Public Health Laboratory tests for antibodies to the hepatitis C 
virus. The presence of antibodies to hepatitis C virus indicates previous or current infection; 
in 80% to 85% of cases the infection persists.29, 30 The sensitivity of the antibody test used in 
this survey is estimated to be 80%. This means that the false negative rate is 20%: one in 
every five who test negative are actually positive. The specificity was 100% which implies 
that all test results which are positive are truly positive. 
The test for antibodies to the HIV virus used in this survey is a measure of ever having been 
infected with HIV. Best knowledge is that people who have ever been infected with HIV re-
main infectious for the duration of their lifetime. Both sensitivity and specificity for the anti-
body test to HIV used in this survey were greater than 99% (manufacturer’s data). 
2.6 Comments and observations 
During the course of the survey, respondents volunteered unsolicited comments about various 
aspects of prison life. Although such comments were not sought, nor collected in a systematic 
manner, the research team considered that some of the comments might be informative. It was 
decided therefore to contact all the survey team after the survey was finished to ask them to 
send us prisoners’ comments and their own observations on prison health care issues. Nine-
teen of the 25 data collectors responded. These replies were analysed by identifying the main 
themes in the respondents’ comments and including actual comments where appropriate. 
2.7 Statistical methods 
Data entry was carried out using an automated procedure31 and was subsequently checked 
manually. Statistical analysis was carried out using JMP IN.32 
Pearson X2 test was used to compare proportions in independent groups of categorical data. 
Multiple logistic regression models were developed to determine which variables best pre-
dicted positive antibody results. Exact 95% confidence intervals were calculated for propor-
tions of binomial variables and for regression adjusted odds ratios. 
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3 - Results 
The results of this study are presented in seven sections. 
3.1 General information including response rate, age and gender profile and prison history 
of the respondents. 
3.2 Prevalence of hepatitis B, hepatitis C and HIV. 
3.3 Hepatitis B vaccination. 
3.4 Prevalence and characteristics of drug use. 
3.5 Reported sexual practice and behaviour. 
3.6 Analysis of factors contributing to increased risk of hepatitis B, hepatitis C and HIV. 
3.7 Synopsis of the respondents’ comments and researchers’ observations on prison health 
care. 
The frequency distributions of the responses to the questions in the questionnaire are given in 
appendix 5. 
Table totals vary throughout as not all respondents answered all questions. 
Most analyses are given by prison group rather than by individual prison to preserve confi-
dentiality; moreover, because of frequent transfers, activities reported in one prison may refer 
to events that took place in a previous prison. 
3.1 – General information 
3.1.1 Response rates 
The governors of the nine selected prisons agreed to the survey; 1,205 out of 1,366 prisoners 
agreed to participate in the survey, an overall response rate of 88%; 1,193 prisoners contrib-
uted an analysable oral fluid sample. The response rate for each prison is shown in Table 1. 
All the participating prisons had high response rates. 
Table 1 – Response rate by prison 
Prison Prison 
population 
on the day of 
the survey 
Exclusions* Sample 
selected 
Number 
responded 
Response rate 
(%) 
High risk 
Mountjay Male 
Mountjoy Female 
The Training Unit 
St Patricks 
Wheatfield 
 
769 
64 
85 
184 
349 
 
3 
3 
1 
15 
2 
 
375 
61 
84 
94 
175 
 
359 
50 
77 
88 
143 
 
96 
82 
92 
94 
82 
Medium risk 
Cork 
Limerick M&F 
Portlaoise 
Shelton Abbey 
 
266 
197 
94** 
41 
 
7 
12 
2 
0 
 
259 
185 
92 
41 
 
288 
142 
80 
38 
 
88 
77 
87 
93 
Total 2049 45 1366 1205# 88 
* Exclusions were those not available for the survey (in court, in hospital, on temporary release or discharged that morn-
ing); already surveyed in previous prison; seriously ill; too dangerous (7 in Cork, 2 in Wheatfield) 
** Political prisoners excluded (approximately 50 – exact number not released for security reasons) 
# 11 respondents did not provide an oral fluid sample and one sample was inadequate for analysis 
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3.1.2 Age and gender of respondents 
The age profile of the respondents was similar to that of the overall population of the nine 
participating prisons at the time of the survey (Figure 1). 
As anticipated, the prison population was very young (Figure 1). Almost half the respondents 
were less than 25 years of age, and 40 (3.5%) were aged 16 or 17. All those under 18 years 
were male and half of them were detained in prisons other than St. Patricks. 
Only 57 (4.7%) of the 1,205 respondents were women. The age distribution was similar in 
men and women (x2 = 4.7, df 3, p-value = 0.243) 
Figure 1 – Age profile of prison population and survey respondents 
 
Pearson x2 = 12.2, df 7, p =.0954 
3.1.3 Prison history 
Details of the respondents’ prison history are summarised in Figure 2. More than one third 
(38.3%, 458) of the respondents said they were currently serving a sentence of more than 
three years and almost half (46.3%, 546) reported having been in prison for more than three 
years during the last 10 years. 
Figure 2 – Prison history of respondents 
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Only two of the 40 respondents aged less than 18 were serving a sentence longer than three 
year. However, three had spent more than three of the past 10 years in prison. Eleven were on 
remand. 
In cross sectional surveys, short sentence prisoners tend to be under represented. In this sur-
vey there were only 157 (13.1%) remand prisoners and 60 (5%) prisoners with a sentence of 
three months or less. Consequently a survey of committal prisoners has also been undertaken 
in order to review this group. The results will be reported separately. 
3.2 Prevalence of hepatitis B, hepatitis C and HIV 
Prevalence was determined using antibody assays of oral fluid (Section 3.2.1). These rates 
were compared with self reported infection status (Section 3.2.2). Although most of those 
with infections reported injecting drug use or sexual risk behaviours, some respondents had 
evidence of infection without apparent risk factors. This finding is discussed in Section 3.2.3. 
3.2.1 Prevalence of antibodies in oral fluid 
Table 2a presents the prevalence of the three blood borne viral infections under investigation 
(hepatitis B, hepatitis C and HIV). Hepatitis C was by far the most common of these in this 
Irish prisoner population; 442 of 1,193 respondents tested positive (37%, CI*: 34.3% – 
39.9%); hepatitis B was less common (104/1,193, 8.7% – CI: 7.2% – 10.5%). HIV was rela-
tively rare: only 24 respondents tested positive (2.0% CI: 1.3% – 3.0%). 
As expected, infection rates were significantly higher in the high risk prisons. For example, 
50.9% (CI: 47.2% – 54.6%) of respondents were positive for hepatitis C in the high risk pris-
ons compared to 16.5% (CI: 13.3% – 20.1%) in the medium risk prisons. The five Dublin 
prisons, Mountjoy Male and Female, St. Patrick’s Institution, the Training Unit and Wheat-
field Place of Detention, have been defined for sampling purposes as high risk prisons as they 
were known to have illicit drug problems (see Methods). The proportion of respondents in 
these five prisons who reported ever injecting drugs was 58%, significantly higher than the 
21% in the medium risk i.e. non Dublin prisons (see Table 7, Section 3.4.1). The high infec-
tion rates in the high risk prisons are consistent with the high infection risks in injecting drug 
users (see below). 
Table 2a – Prevalence of hepatitis B and C and HIV by prison category 
 All 
Total: 1193 
No. (%) 
95% CI 
High risk 
Total: 713 
No. (%) 
95% CI 
Medium risk 
Total: 480 
No. (%) 
95% CI 
Test of association 
Hepatitis B positive 104 (8.7) 
7.2-10.5 
87 (12.2) 
9.9-14.8 
17 (3.5) 
2.1-5.6 
Hepatitis B positive prisoners were 
significantly more likely to reside in 
a high risk prison 
Pearson x2 = 27, df = 1, p < .0001 
Hepatitis C positive 442 (37.0) 
34.3-39.9 
363 (50.9) 
47.2-54.6 
79 (16.5) 
13.3-20.1 
Hepatitis C positive prisoners were 
significantly more likely to reside in 
a high risk prison 
Pearson x2 = 146, df = 1, p < .0001 
HIV positive 24 (2.0) 
1.3-3.0 
20 (2.8) 
1.7-4.3 
4 (0.8) 
0.2-2.1 
HIV positive prisoners were signifi-
cantly more likely to reside in a 
high risk prison 
Pearson x2 = 5.6, df = 1, p = .0174 
 
                                                        
* CI denotes 95% confidence interval. 
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Each of the three infections was far more common in those who reported ever injection drugs 
than in non users (Table 2b). Hepatitis B and HIV occurred more frequently in prisoners aged 
3.0 or over than in those under 30 years of age; hepatitis C was more frequent in those under 
30 than in those aged 30 or over (Table 2c). the highest infection rate for hepatitis C was 
found in those aged 20-24 years (not shown in table). Infection rates for hepatitis B and C 
were slightly higher in the women prisoners although the differences were not significantly 
different (Table 2d). 
Four of the 40 respondents under 18 years of age were hepatitis C positive; none were hepati-
tis B or HIV positive. 
Table 2b – Prevalence of hepatitis B and C and HIV by injecting drug use 
 IDU 
Total: 509 
No. (%) 
95% CI 
Non IDU 
Total: 669 
No. (%) 
95% CI 
Test of association 
Hepatitis B positive 94 (18.5) 
15.2-22.1 
10 (1.5) 
0.7-2.9 
Testing positive for hepatitis B was significantly 
associated with reported injecting drug use 
Pearson x2 = 103.5, df = 1, p < .0001 
Hepatitis C positive 414 (81.3) 
77.7-84.6 
25 (3.7) 
2.4-5.5 
Testing positive for hepatitis C was significantly 
associated with reported injecting drug use 
Pearson x2 = 744.5, df = 1, p < .0001 
HIV positive 18 (3.5) 
2.1-5.5 
6 (0.9) 
0.3-1.9 
Testing positive for HIV was significantly more 
associated with reported injecting drug use 
Pearson x2 = 10.1, df = 1, p = .0015 
Table 2c – Prevalence of hepatitis B and C and HIV by age 
 < 30 yr 
Total: 797 
No. (%) 
95% CI 
> 30 yr 
Total: 340 
No. (%) 
95% CI 
Test of association 
Hepatitis B positive 52 (6.5) 
4.9-8.5 
47 (13.8) 
10.3-18.0 
Testing positive for hepatitis B was significantly 
less likely among respondents under 30 years of 
age. 
Pearson x2 = 16, df = 1, p < .0001 
Hepatitis C positive 327 (41.0) 
37.6-44.5 
91 (26.8) 
22.1-31.8 
Testing positive for hepatitis C was significantly 
more likely in respondents under 30 years of age. 
Pearson x2 = 20.9, df = 1, p < .0001 
HIV positive 8 (1.0) 
0.4-1.8 
15 (4.4) 
2.7-7.5 
Testing positive for HIV was significantly less 
likely in respondents under 30 years of age. 
Pearson x2 = 14, df = 1, p = .0002 
Table 2d – Prevalence of hepatitis B and C and HIV by gender 
 Women 
Total: 57 
No. (%) 
95% CI 
Men 
Total: 1136 
No. (%) 
95% CI 
Test of association 
Hepatitis B positive 7 (12.3) 
5.1-23.7 
97 (8.5) 
7-10.3 
Pearson x2 = 0.9, df = 1, p = .3284 
NS 
Hepatitis C positive 24 (42.1) 
29.1-55.9 
418 (36.8) 
34.0-37.7 
Pearson x2 = 0.7, df = 1, p = .4180 
NS 
HIV positive 1 (1.7) 
.04-9.4 
23 (2) 
1.3-3.0 
Pearson x2 = 0.02, df = 1, p = .8872 
NS 
NS = not significant 
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Figure 3 shows the inter-relationship between the three infections. 38.5% of prisoners had 
evidence of infection with at least one virus. Most of those who had antibodies to hepatitis B 
or HIV also had antibodies to one or more of the other two viruses (90% and 83% respec-
tively) whereas only 23% (101/443) of those infected with hepatitis C had an additional infec-
tion. 
Figure 3 – Number (%) of respondents oral fluid test positive for hepatitis B and C and 
HIV and the overlap between the infections, N = 1193 (100%) 
 
3.2.2 Comparison of prevalence from oral fluid assays and from self reporting 
The self reported prevalence for each infection was lower than that derived from the oral fluid 
assays (Table 3). Using self reports to estimate prevalence within the prisons would have se-
riously under-estimated the scale of the infection problem. The majority of respondents said 
they had not been tested previously. Others did not know whether they had been tested for the 
viruses, and of those who said they had been previously tested, a considerable number said 
they did not know the result. 
Table 3 – Comparison of proportions positive for oral fluid test with self reported status, 
as a percentage of the total survey population and as a percentage of those 
previously tested 
  Oral fluid 
test 
 
No. (%) 
Self reported status 
as a % of total 
survey population 
No. (%) 
Self reported status 
as a % of those 
tested  
No. (%) 
Hepatitis B Positive 
Negative 
Do not know 
Total 
104 (8.7) 
1089 (91.3) 
 
1193 (100) 
63 (5.2) 
 
 
1205 (100) 
63 (19.6) 
209 (64.9) 
50 (15.5) 
322 (100) 
Hepatitis C Positive 
Negative 
Do not know 
Total 
442 (37) 
751 (63) 
 
1193 (100) 
232 (19.2) 
 
 
1205 (100) 
232 (67.8) 
76 (22.2) 
34 (9.9) 
342 (100) 
HIV Positive 
Negative 
Do not know 
Total 
24 (2) 
11769 (98) 
 
1193 (100) 
20 (1.7) 
 
 
1205 (100) 
20 (4.5) 
370 (83.5) 
51 (12) 
443 (100) 
 
 
12 
Results 
…………………………………………………………………………………..……………………………….. 
 
 
The respondents who reported previous tests for any of these infections differed from the 
wider group in that they were more likely to be drug users. For example, those who reported 
having had a test for hepatitis C were eight times more likely to be injecting drug users 
(59.3% of injectors said they had had a test compared to only 7.1% of non injectors); those 
reporting a test for hepatitis B or HIV were almost four times more likely to be injecting drug 
users (see Appendix 5). Consequently the apparent prevalence for all three infections in the 
previously tested group (self reported status) was considerably higher than in the overall 
group. 
Tables 4a-4c show the number of respondents who reported a previous negative test result but 
tested positive to the oral fluid assay and vice versa. (Note: The numbers in these tables relate 
only to respondents who knew their test results.) Over a third (28/75) who claimed to have 
had a negative test result for hepatitis C had a positive oral fluid test result. The proportion of 
those testing positive but reporting negative was lower for hepatitis B (10%, 21/208) and for 
HIV (2%, 8/367). It was surprising to note that 58% (11/19) of those who reported being HIV 
positive tested negative on the oral fluid assay, while almost half (30/63) who self reported 
being hepatitis B positive tested negative. Eleven (4.8%) of those who reported that they were 
hepatitis C positive were negative on the oral fluid test. Possible reasons for these discrepan-
cies include: mistakes in filling out the questionnaire, misunderstanding the question, deliber-
ate misrepresentation, change in antibody status since the previous test, and test error (includ-
ing discrepancies between different laboratories). 
Table 4a – Self reported hepatitis B status and the oral fluid test results 
Oral fluid 
Test result 
Reported hepatitis B result 
Positive Negative 
 
Positive 
Negative 
33 21° 
30* 187 
54 
217 
 63 208 271 
 ° Respondent reported negative hepatitis B status but tested positive 
 * Respondent reported positive hepatitis B status but tested negative 
Table 4b – Self reported hepatitis C status and the oral fluid test results 
Oral fluid 
Test result 
Reported hepatitis C result 
Positive Negative 
 
Positive 
Negative 
218 28° 
11* 477 
241 
63 
 229 75 304 
 ° Respondent reported negative hepatitis C status but tested positive 
 * Respondent reported positive hepatitis C status but tested negative 
Table 4c – Self reported HIV status and the oral fluid test results 
Oral fluid 
Test result 
Reported HIV result 
Positive Negative 
 
Positive 
Negative 
8 8° 
11* 359 
16 
370 
 19 367 386 
 °Respondent reported negative hepatitis HIV status but tested positive 
 * Respondent reported positive hepatitis HIV status but tested negative 
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3.2.3 Infections among respondents with no risk factors 
There were 536 (out of 1.205) respondents who reported having none of the main risk factors 
(i.e. said they had never injected drugs, never had anal sex with a man either inside or outside 
prison, and never been treated for a sexually transmitted infection). Among this subgroup 
there were seven who were hepatitis B positive, 28 hepatitis C positive and three HIV posi-
tive; three of these were positive for both hepatitis B and C. all were men. 
Ninety-two (out of 536) had reported smoking heroin in the last year. When these were ex-
cluded, there remained five who were hepatitis B positive, nine hepatitis C positive and three 
HIV positive. All were unaware of being positive except one who had reported a previous 
positive hepatitis C result. 
Deliberate misrepresentation may explain these infections in respondents with no apparent 
risk factors. They may have had a partner whose sexual history was unknown to them. Alter-
natively they may have been infected through tattoos, needle stick injuries, infected blood 
products or other unidentified routes of infection such as sharing razors and/or toothbrushes. 
Overcrowding in prison may be another contributing factor. 
3.3 Uptake of hepatitis B vaccine 
Self reported vaccine uptake rate by prison is shown in Table 5. Vaccine uptake overall was 
disappointingly low: 
• 28.9% of respondents reported completing three doses of hepatitis B 
• 19.0% completed one or two doses 
• 52.1% reported not receiving hepatitis B vaccine. 
In only 4 prisons (Mountjoy Male and Female, Training Unit and Portlaoise) were the major-
ity of respondents immunised, partially or fully. In the other prisons, including two of the high 
risk Dublin prisons (Wheatfield and St. Patricks), the majority of prisoners reported not hav-
ing had any doses of hepatitis B vaccine. 
Only one (2.5%) of the 40 respondents under 18 had completed three doses of hepatitis B 
vaccine; a further three (7.5%) had received one or two doses. Vaccine uptake rates were 
equally low in those who were still susceptible to hepatitis B infection i.e. respondents whose 
antibody status was hepatitis B negative. (see Appendix 6) 
Table 5 – Reported hepatitis B vaccine coverage in each prison 
Prison Completed 
3 doses 
No. (%) 
Completed 
1 or 2 doses 
No. (%) 
Did not receive 
Vaccine 
No. (%) 
Total 
Portlaoise 37 (47.4) 24 (30.8) 17 (21.8) 78 
Mountjoy female 22 (44.9) 7 (14.3) 20 (40.8) 49 
Training Unit 30 (43.5) 21 (30.4) 18 (26.1) 69 
Mountjoy male 149 (43.3) 96 (27.9) 99 (28.8) 344 
Wheatfield 19 (16.1) 21 (17.8) 78 (66.1) 118 
Limerick male 15 (14.2) 11 (10.5) 79 (75.3) 105 
St Patricks 10 (13.7) 6 (8.2) 57 (78.1) 73 
Cork 20 (11) 10 (5.5) 151 (83.5) 181 
Shelton Abbey 2 (7.1) 4 (14.2) 22 (78.6) 28 
Limerick female 0 (0) 0 (0) 6 (100) 6 
Total 304 (28.9) 200 (19.0) 547 (52.1) 1051 
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Table 6a shows the proportions with hepatitis B vaccine by length of time spent in prison over 
the last ten years. As it is Department of Justice, Equality and Law Reform policy that all 
prisoners sentenced for eight months (equivalent to serving six months) or more should be 
offered hepatitis B vaccination, it is not surprising that completion rates were highest in those 
who had spent more than three of the last 10 years in prison. However, there were large num-
bers who had spent more than six months in prison over the last 10 years who remained un-
vaccinated. High proportions of short sentences in some prisons are unlikely to account fully 
for low vaccination rates. 
There appears to be an active vaccination programme in the adult prisons of the Mountjoy 
complex. Overall however, it is clear that the vaccination programme is not reaching many of 
those at risk (see Tables 6b and 6c), and further efforts are required to rectify this shortfall. 
Table 6a – Hepatitis B vaccination coverage by time spent in prison in the last 10 years 
Hepatitis B vaccine status Time in prison in the past 10 years 
< 3 years  > 3 years 
No./Total (%) No./Total (%) 
Test of association 
1 or more doses 182/535 (34.0) 321/500 (64.2) Pearson x2 = 94.2, df = 1, p < .0001 
Respondents who had spent more than 
3 years in prison were significantly 
more likely to have started a course of 
hepatitis B vaccine. 
3 doses completed 
(of those who had at least 1 dose) 
90/182 (49.5) 213/321 (66.3) Pearson x2 = 13.6, df = 1, p < .0001 
Of those who started vaccination, the 
respondents in prison over 3 yrs were 
more likely to report completing the 
course. 
Table 6b – Hepatitis B vaccination coverage by injecting drug use  
Hepatitis B vaccine status Injecting drug users 
IDU Non IDU 
No./Total (%) No./Total (%) 
Test of association 
1 or more doses 300/480 (62.5) 321/500 (64.2) Respondents who were IDUs were 
more likely to have commenced a 
course of vaccine. 
Pearson x2 = 73.5, df = 1, p < .0001 
3 doses completed 
(of those who had at least 1 dose) 
184/300 (61.3) 118/202 (58.4) Of those who started vaccination, 
IDU respondents were not more 
likely to report completing the 
course. 
Pearson x2 = 1.9, df = 1, p = . 169 
Table 6c – Hepatitis B vaccination coverage by hepatitis B status  
Hepatitis B vaccine status Hepatitis status (oral fluid) 
Negative Positive 
No./Total(%) No./Total(%) 
Test of association 
1 or more doses 447/948 (47.2) 54/97 (55.7) Respondents who were oral fluid 
negative for hepatitis B were not 
more likely to have commenced 
hepatitis B vaccine. 
Pearson x2 = 2.6, df = 1, p = .1097. 
3 doses completed 
(of those who had at least 1 dose) 
261/447 (58.4) 41/54 (75.9) Of those who started vaccination, 
oral fluid positive respondents were 
more likely to report completing 
the course. 
Pearson x2 = 8.3, df = 1, p = .004. 
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3.4 Drug use 
3.4.1 Reported drug use 
Table 7 shows that 545 respondents said they had smoked heroin in the last year and 514 
stated they had (ever) injected drugs. The proportion reporting drug use was much higher in 
the high risk prisons. Overall, 630 of the 1,205 respondents said hey had used heroin (Figure 
4). Most, but not all, of those who said they had smoked heroin in the last year had also in-
jected drugs and vice versa. 
Fifteen of the 40 respondents under 18 years of age reported smoking heroin in the last year 
and 10 reported ever injecting drugs. 
Table 7 – Proportion of respondents who smoked heroin or ever injected drugs by prison 
category (high and medium risk) 
 All 
No./Total (%) 
High 
No./Total (%) 
Medium 
No./Total (%) 
Test of association 
Smoked heroin in 
the last 12 months 
545/1187 (45.9) 408/711 (57.4) 137/476 (28.8) Smoking heroin in the last year was 
significantly more common in high 
risk prisons 
Pearson x2 = 93.9, df = 1, p <.0001 
Ever injected drugs 514/1188 (43.2) 414/712 (58.2) 100/477 (21) Injecting drug use was significantly 
more common in high risk prisons 
Pearson x2 = 161.5, df = 1, p= <.0001 
Figure 4 – Inter-relationship between smoking heroin and injecting drug use N=1179 
(100%)* 
 
 
 
 
16 
Results 
…………………………………………………………………………………..……………………………….. 
 
 
Women prisoners were more likely to smoke heroin and/or inject drugs. Almost 60% of 
women respondents reported smoking heroin in the last year compared to 45.2% of male re-
spondents; 59.6% of women respondents reported ever injecting drugs compared to 42.4% of 
men (Table 8). 
Table 8 – Proportion of respondents who smoked heroin or ever injected drugs by  
gender 
 Women 
No./Total (%) 
Gender Men 
No./Total (%) 
Test of association 
Smoked heroin in 
the last year 
34/57 (59.6) 511/1130 (45.2) Women were significantly more likely than 
men to report smoking heroin. 
Pearson x2 = 4.5, df = 1, p = 0.0329 
Ever injected 34/57 (59.6) 480/1131 (42.4) Women were significantly more likely than 
men to report drug use. 
Pearson x2 = 6.5, df = 1, p = 0.0105 
More than half the injectors said they had commenced injecting before their 18th birthday 
(Figure 5). Most had been injecting for a considerable time period: 92% had first injected 
more than three years ago. Over 70% of injectors said they had injected drugs in the week 
prior to committal (55.9% in the previous 24 hours) Figure 6). This suggests that most were 
current drug users. 
Figure 5 – Age started injecting drugs 
 
Figure 6 – Last time drug users injected before committal to prison 
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3.4.2 Reported drug using behaviour in prison 
104 prisoners (8.6% of the 1,205 respondents), or fifth of injectors (104/506), said they first 
started injecting drugs while in prison. 
Drug use within prison was common. For example, 45% of the 334 respondents with a history 
of injecting drug use who had been in prison for more than three months, stated that they had 
injected drugs in previous month; 103 (31%) reported injecting 1 to 19 times in the previous 
month while 48 (14%) said that they had injected more than 20 times (Figure 7). 
Six of the 10 injectors 18 years of age reported injecting in the previous month. 
Figure 7 – Frequency of injecting in the month prior to the survey among injecting drug 
users resident in prison for more than 3 months on this sentence (n = 334) 
 
Figure 8 shows that injectors were significantly more likely to share ‘works’ (i.e. injecting 
equipment such as needles, syringes, filters, spoons) one or more times inside prison than 
outside: 
• 58% said they shared all injecting equipment while in prison. 
• 37% said they shared all injecting equipment in the month before coming into prison. 
(Note. No information was asked about the number of times injecting equipment was shared). 
Figure 8 – Frequency of sharing injecting equipment in the month before committal  
versus sharing in prison 
 
Pearson x2 = 76.5, df = 4, p <.0001 
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Five of the 10 injectors under the age of 18 reported sharing injecting equipment in the month 
before coming into prison, and two said they had shared injecting equipment in prison. 
Those who shared injecting equipment were significantly more likely to be infected with 
hepatitis C than those who did not share it. Almost 87% of injectors who said they had shared 
injecting equipment in the month before coming into prison were infected with hepatitis C 
compared to 75.3% of those who had not shared outside in the month before committal (Pear-
son x2 = 8.9 df 1, p = 0.0023). The excess risk of sharing injecting equipment within the 
prison environment was even greater than sharing outside: 89.1% of those who said they had 
ever shared inside prison were infected with hepatitis C compared to 62.2% of those who had 
not shared in prison (x2 = 45.3 df 1, p <.0023). 
3.4.3 Methadone treatment prior to committal 
Just over a third of the injecting drug users (187/502) said they were on a methadone pro-
gramme prior to committal. This included three of the 10 injectors aged less than 18. Those 
committed to prison within the last three years were more likely to have been on a methadone 
programme prior to committal than those who had been in prison for more three years on the 
current sentence. (Table 9). 
Table 9 – Number (%) on methadone at committal by length of time spent in prison on 
this sentence 
Methadone Time in prison on this sentence 
<3 years > 3 years Test of association 
Yes 168/472 (39.3) 16/71 (22.5) Respondents in prison for more than 3 years 
were significantly less likely to have been on 
a methadone programme prior to committal 
Pearson x2 = 7.4, df = 1, p = .0066 
Over half of those who said they were on methadone at committal (101/187) said they had 
injected on the day before entering the prison. A further 49 (25%) said they injected in the 
month before entering the prison. Only 37 (20%) respondents said they had not injected in the 
month prior to imprisonment. Fifteen of thee 37 (i.e. on methadone at committal and had not 
injected in the month prior to imprisonment) had recommended injecting drug use in prison. 
• 4 said they had injected more than 20 times in the previous month 
• 14 reported that they had shared equipment in the prison 
• 10 tested positive for hepatitis C 
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3.5 Sexual practices 
The sexual risk factors reported by respondents are shown in Table 10 separately for injecting 
drug users and non users. It was our impression that these questions were the least likely to 
have been answered truthfully. 
Most respondents reported heterosexual activity in the year prior to committal. Only 28 men 
reported that they had ever had anal sex with a man (2.5% of the 1,116 men who responded to 
the question), and 20 (1.8% of the 1,087 who answered the question) reported having had anal 
sex with a man while prison. These two groups were not necessarily the same men. For ex-
ample six men reported anal sex in prison having previously denied ever having sex with an-
other man. It may be that this behaviour was, for them, atypical, and would not have occurred 
outside prison. 
Other practices of note are listed below: 
• Condom use (always or sometimes) was infrequent, especially by those reporting ho-
mosexual intercourse. However, these questions did not differentiate between mo-
nogamous relationships and casual partners. 
• One eighth of respondents had been treated for sexually transmitted infections. 
• Sexually transmitted infections were more common among injecting drug users. 
Table 10 – Reported sexual risk factors 
 All 
No./Total (%) 
IDU 
No./Total (%) 
IDU 
No./Total (%) 
Heterosexual intercourse in the 12 
months prior to committal 
1088/1182 (92) 483/511 (94.5) 596/661 (90.2) 
Use condoms during heterosexual 
intercourse 
347/1026 (33.8) 138/451 (30.6) 205/566 (36.2) 
Men ever have anal sex with men 28/1116 (2.5) 15/474 (3.40 12/633 (1.9) 
Use condoms during male 
homosexual intercourse 
4/21 (19) 1/14 (7.1) 3/7 (42.9) 
Men ever have anal sex with men 
in prison 
20/1087 (1.8) 9/464 (2) 10/613 (1.6) 
Ever treated for STI* 147/1165 (12.6) 87/503 (17.3) 60/653 (9.2) 
* Sexually transmitted infection 
Tables 11-13 show the frequency of the various sexual practices among those who tested 
positive for one or more of the 3 infections. Relevant features were: 
• HIV or hepatitis B positive men were more likely to have reported anal sex with men. 
• Positive status of each of the three infections was more common in those reporting a 
history of treatment for sexually transmitted infections. (A history of sexually transmit-
ted infections is an indicator of “unsafe sex”). 
• HIV positive respondents were more likely to use condoms during heterosexual inter-
course than those who were HIV negative. One interpretation of this finding is that 
HIV infected respondents were attempting to protect their partner(s). 
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Table 11 – Reported sexual risk factors for hepatitis B 
 Hepatitis B 
Positive Negative 
No./Total (%) No./Total (%) 
Test of association 
Use condoms during 
heterosexual intercourse  
29/90 (32.2) 317/931 (34.0) Pearson x2 = 0.12, df = 1, p = .7266 
NS 
Men ever have anal sex  
with men 
7/95 (7.4) 21/1013 (2.1) Respondents who tested positive for hepa-
titis B were more likely to have report that 
they had anal sex with another man 
Pearson x2 = 9.9, df = 1, p =.0017 
Men ever have anal sex 
with men in prison 
2/92 (2.2) 18/987 (1.8) Pearson x2 = 0.06, df = 1, p = .8117 
NS 
Ever treated for STI* 26/101 (25.7) 121/1057 (11.4) Respondents who tested positive for hepa-
titis B were more likely to have reported 
having treatment for STI 
Pearson x2 = 17, df = 1, p <.0001 
* Sexually transmitted infection 
NS = Not significant 
Table 12 – Reported sexual risk factors for hepatitis C 
 Hepatitis C 
Positive Negative 
No./Total (%) No./Total (%) 
Test of association 
Use condoms during 
heterosexual intercourse  
121/396 (30.6) 225/625 (36.0) Pearson x2 = 3.2, df = 1, p = .0733 
NS 
Men ever have anal sex  
with men 
12/412 (2.9) 16/696 (2.3) Pearson x2 = 0.4, df = 1, p = .5293 
NS 
Men ever have anal sex 
with men in prison 
7/399 (1.7) 13/680 (1.9) Pearson x2 = 0.03, df = 1, p = .8532 
NS 
Ever treated for STI* 73/432 (16.9) 74/726 (10.2) Respondents who tested positive for hepa-
titis C were more likely to have reported 
having treatment for STI 
Pearson x2 = 11, df = 1, p =.0009 
* Sexually transmitted infection 
NS = Not significant 
Table 13 – Reported sexual risk factors for HIV 
 HIV 
Positive Negative 
No./Total (%) No./Total (%) 
Test of association 
Use condoms during 
heterosexual intercourse  
12/19 (63.2) 334/1002 (33.3) Respondents who tested positive for HIV were 
more likely to use condoms. 
Pearson x2 = 7.4, df = 1, p = .0065 
Men ever have anal sex  
with men 
5/23 (21.7) 23/1085 (2.1) Male respondents who tested positive for HIV 
were more likely to have had anal sex with 
another man 
Pearson x2 = 35.2, df = 1, p <.0001 
Men ever have anal sex 
with men in prison 
3/23 (13.0) 17/1056 (1.6) Male respondents who tested positive for HIV 
were more likely to have had anal sex with 
another man in prison 
Pearson x2 = 16.2, df = 1, p <.0001 
Ever treated for STI* 9/24 (37.5) 138/1134 (12.2) Respondents who tested positive for HIV were 
more likely to have reported having had treat-
ment for STI 
Pearson x2 = 13.6, df = 1, p = .0002 
* Sexually transmitted infection 
NS = Not significant 
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3.6 Risk factors for infection 
Analysis of individual risk factors showed that by far the most important predictor of both 
hepatitis B and hepatitis C was a history of injecting drug use. The link between injecting 
drug use and hepatitis C was particularly strong. The strongest predictor of HIV infection was 
a history of anal sex with men. However, as the numbers involved were small, this was a less 
important factor in the overall picture than injecting drug use. 
In order to clarify the links between these various risk factors, the factors were combined in 
multivariate analyses (logistic regression), the main findings of which are described below. 
The relationships presented below are those that remained statistically significant after taking 
account of the inter-linking of risk behaviours. (The associations are expressed as odds ratios 
(OR) adjusted or confounding). 
• Respondents with evidence of hepatitis B infection were more likely to be injecting 
drug users, to be older, and to have been treated for sexually transmitted infections. Af-
ter taking into account differences between respondents, those who reported ever in-
jecting drugs were 22 times more likely to be hepatitis B positive than those who did 
not report injecting (adjusted OR 21.6, CI**10.9-47.6). Respondents aged 35 years or 
older were 10 times more likely to be hepatitis B positive than those aged 16-19 years 
(adjusted OR 9.7, CI 3.8-28.6). (Table 14a) 
• Those positive for hepatitis C were very likely to be injecting drug users (adjusted OR 
80.8, CI 47.9-143); they tended to be younger, smoke heroin (adjusted OR 2, CI 1.2-
3.3), and the risk of infection increased with increasing time spent in prison during the 
last 10 years. (Table 14b) 
• Individuals who reported ever injecting drugs were 3 times as likely to be HIV positive 
as non injectors (adjusted OR 3.4, CI 1.3-9.5), as were individuals who reported ever 
having been treated for a sexually transmitted infection (adjusted OR 3,0, CI 1.2-7.4). 
Men who had anal sex with other man were 8 times (adjusted OR 8.4, CI 2.4-25.1) 
more likely to be HIV positive (Table 14c). The total number who tested positive for 
HIV was very small (24/1993) and the numbers with each of the three main risk factors 
were even smaller (IDU: 18, STI: 9 and men having anal sex with men: 5), and there 
was a considerable degree of overlap (statistical interaction). Therefore inferences from 
this model are limited. 
Table 14a – Logistic regression model to identify determinants of hepatitis B infection 
 Total 
sample 
1193 
No. 
Hepatitis B 
negative 
1089 
No. 
Hepatitis B 
positive 
104 
No. 
Prevalence of 
hepatitis B 
 
% 
Odds 
ratio 
95% CI p-value 
Ever injected 
drugs 
No 
Yes 
Missing 
 
 
670 
509 
14 
 
 
659 
415 
 
 
10 
94 
 
 
1.5 
18.5 
 
 
1 
21.6 
 
 
 
10.9-47.6 
 
 
 
<.0001 
Age group 
16-19 
20-24 
25-34 
35+ 
Missing 
 
177 
367 
399 
194 
56 
 
168 
341 
362 
167 
 
9 
26 
37 
27 
 
5.1 
7.1 
9.3 
13.9 
 
1 
1.5 
2.3 
9.7 
 
 
0.6-4.1 
1-6.3 
3.8-28.6 
 
 
.4106 
.0720 
<.0001 
Ever treated for 
STI* 
No 
Yes 
Missing 
 
 
1011 
147 
35 
 
 
936 
121 
 
 
75 
26 
 
 
7.4 
17.7 
 
 
1 
1.9 
 
 
 
1.1-3.3 
 
 
 
.0183 
Whole model x2 = 142 R2 = .22 p <.0001 
* Sexually transmitted infection 
                                                        
** CI denotes 95% confidence interval 
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Table 14b – Logistic regression model to identify determinants of hepatitis C infection 
 Total 
sample 
1193 
No. 
Hepatitis C 
negative 
751 
No. 
Hepatitis C 
positive 
442 
No. 
Prevalence of 
hepatitis C 
 
% 
Odds 
ratio 
95% CI p-value 
Ever injected 
drugs 
No 
Yes 
Missing 
 
 
669 
509 
14 
 
 
644 
95 
 
 
25 
414 
 
 
4.8 
80.2 
 
 
1 
80.8 
 
 
 
47.9-143 
 
 
 
<.0001 
Age group 
16-19 
20-24 
25-34 
35+ 
Missing 
 
177 
367 
399 
194 
56 
 
130 
192 
241 
156 
 
47 
175 
158 
38 
 
26.5 
47.7 
39.6 
19.6 
 
1 
2.8 
1.8 
1.9 
 
 
1.5-5.3 
.9-3.4 
.8-4.5 
 
 
.0016 
.754 
.1133 
Total amount of 
time spent in 
prison over the 
last 10 years 
<3 months 
3-11 months 
12-36 months 
>3 years 
Missing 
 
 
 
 
136 
197 
299 
538 
23 
 
 
 
 
116 
157 
197 
261 
 
 
 
 
20 
39 
102 
277 
 
 
 
 
15.4 
20.3 
33.8 
51.3 
 
 
 
 
1 
2.9 
4.0 
6.5 
 
 
 
 
 
1.2-6.9 
1.9-8.6 
3.2-13.3 
 
 
 
 
 
.0145 
.0003 
<.0001 
Ever smoked 
heroin in the 
previous 12 
months 
No 
Yes 
Missing 
 
 
 
 
637 
540 
16 
 
 
 
 
555 
187 
 
 
 
 
82 
353 
 
 
 
 
12.9 
65.4 
 
 
 
 
1 
2 
 
 
 
 
 
1.2-3.3 
 
 
 
 
 
.0072 
Whole model x2 = 847.7 R2 = .58 p <.0001 
Table 14c – Logistic regression model to identify determinants of HIV infection 
 Total 
sample 
1193 
No. 
HIV 
negative 
1169 
No. 
HIV 
positive 
24 
No. 
Prevalence 
of HIV 
 
% 
Odds 
ratio 
95% CI* p-value 
Ever injected 
drugs 
No 
Yes 
Missing 
 
 
669 
509 
14 
 
 
663 
491 
 
 
6 
18 
 
 
0.9 
3.5 
 
 
1 
3.4 
 
 
 
1.3-9.5 
 
 
 
.0129 
Ever treated for 
STI 
No 
Yes 
Missing 
 
 
1011 
147 
35 
 
 
996 
138 
 
 
15 
9 
 
 
1.5 
6.1 
 
 
1 
3 
 
 
 
1.2-7.4 
 
 
 
.0180 
Men ever had 
anal sex with 
men 
No 
Yes 
Missing 
 
 
 
1080 
28 
85 
 
 
 
1062 
23 
 
 
 
18 
5 
 
 
 
1.7 
17.9 
 
 
 
1 
8.4 
 
 
 
 
2.4-25.1 
 
 
 
 
.0003 
Whole model x2 = 28.5 R2 = .13 p <.0001 
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Injecting drug use was clearly the biggest contributor to infection with hepatitis B and hepati-
tis C and was also important in HIV infection. Consequently the data have been analysed to 
identify behaviours which contributed to the ‘riskiness’ of injecting. The relationships below 
are those that remained significant after taking account of the inter-linking of risk behaviours 
(the associations are expressed as odds ratios (OR) adjusted for confounding). The detailed 
models are presented in Appendix 7a-7c. 
• Injecting drug users aged 30 or over were 4 times more likely than injectors under 30 
(adjusted OR 4.1. CI* 2.4-7.0) to have evidence of hepatitis B infection. Injectors with 
a history of treatment for sexually transmitted infection had twice the hepatitis B risk of 
those who had not reported treatment for sexually transmitted infection (adjusted OR 
2.1, CI 1.1-3.7) Length of time injecting was also associated with a slight increase in 
risk of infection. The fact that infection rates remained higher in older respondents, 
even after controlling for the increased length of injecting that would be expected in 
older individuals, suggests a cohort effect. 
• Injectors who had spent longer in prison over the last 10 years were more likely to have 
evidence of hepatitis C infection. Those who had shared needless in prison (adjusted 
OR 2.9, CI 1.5-5.7) or who reported frequent injecting in the month prior to the survey 
were also at increased risk of hepatitis C infection. 
• Injectors who had been treated for a sexually transmitted infection had a higher risk of 
HIV than drug injectors who had not reported treatment for sexually transmitted infec-
tions (adjusted OR 2.8, CI 0.9-8.1). HIV positive injectors were more likely to report 
using condoms in heterosexual intercourse than HIV negative injectors; presumably 
this reflects an attempt to protect their partners. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                        
* CI denotes 95% confidence interval 
 
24 
Results 
…………………………………………………………………………………..……………………………….. 
 
 
3.7 Comments and observations 
On completion of the study, the interviewers were sent a one-page questionnaire, with the 
following questions: 
“During your conversations with prisoners while conducting the survey, were any issues 
raised relating to health care in the prisons? Please describe” 
“Do you have any observations to make about the prison health care service? Please describe” 
Answers were received from 19/25 of the interviewers. A number of issues emerged from the 
answers. These are elucidated below, with verbatim quotes to exemplify each issue. The 
source (interview 1 – 19) is given in brackets at the end of each quote. 
Many comments were negative. However, these should interpreted bearing in mind that those 
with complaints saw the survey as an opportunity to voice their dissatisfaction. 
3.7.1 Medical care 
There were a number of comments about the standards of medical care, the attitudes of some 
of the prison doctors and variations between medical care in different prisons: 
‘Praise for some doctors, criticism for others – Mountjoy and Cork in particular’ (3) 
‘Difficulty seeing a doctor when required’ (14) 
‘The doctor here doesn’t give a shit’ (inmate in Mountjoy men’s)’ (14) 
‘Lack of confidence in prison doctor’ (17) 
‘Positions held by semi-retired, not so dynamic/innovative medics’ (14) 
‘A few prisoners mentioned that there were a few good doctors attached to specialised units 
in the prison. One prisoner said Dr. x was very good man ‘he speaks to us and listens to our 
problems’, ‘he treats us like humans’. Interestingly many complaints were about the Drs 
rather than the POs.’ (19) 
‘The respondents were in general fairly negative about the health services provided in pris-
ons. The medical officers in one of the prisons were severely criticised – it was stated that 
respondents always had to stand during medical consultations, and physical examinations 
were rarely, if ever, conducted.’ (19) 
3.7.2 Confidentiality 
Concerns were expressed about the confidentiality of medical services and the medical or-
derly system. This is particularly relevant in the context of the new appointments of nurses to 
the prison health care system. As it stands, these nurses will also have the status of prison of-
ficers. Prisoners’ anxieties about confidentiality are likely to be reinforced by this decision. 
‘Concern re. Confidentiality of medical records’ (17) 
‘Lack of confidentiality – medical orderlies are prison officers’ (3) 
‘Confidentiality was not respected according to prisoners. The governor, POs and other in-
mates often knew infected prisoners through leakage of info.’ (19) 
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3.7.3 Treatment for drug users 
A number of comments were made about the inadequacy of treatment facilities for drug users. 
‘Some prisoners felt strongly about the lack of support services for prisoners wishing to break 
a drug addiction.’ (2) 
‘Many expressed the view that methadone should be more available in prison and that it 
should be possible to obtain maintenance methadone. Most felt that the detox on offer was to 
rapid, at too low a dose (Mountjoy men’s)’ (12). 
‘Methadone was not being given to responders who were on a programme on the outside’(18) 
‘Need for methadone maintenance programmes +/- needle exchange’ (9) 
‘Requests for needle exchange services to be made available’ (5) 
3.7.4 Hepatitis B, hepatitis C and HIV 
Not surprisingly, given that a prevalence survey was in progress, there were a number of spe-
cific factual questions about blood borne viral infections. Although some Dublin prisoners 
were well informed, it was evident that others were unclear about how such infections are 
transmitted. There appears to be a need for more education about methods of transmission, 
and the implications for future health of having these infections. Anxieties were expressed 
about testing for the presence of these infections while in prison. There were also observa-
tions about practices that might result in the transmission of such infections (such as sharing 
razors). Comments about the adequacy of the existing hepatitis B vaccination programme 
were also made: 
‘Prisoners requested info on hepatitis B/hepatitis C – implications for their present and future 
health – didn’t know about it (and were positive)’ (5) 
‘Non-drug users worried about their exposure to infections diseases’ (5) 
‘A specific question – can hepatitis and HIV be contracted through sharing a cigarette or an 
apple?’ (7) 
‘Another asked  if he could have an HIV test done in prison and get the result.’ (10) 
‘Some prisoners mention that they would never have a test for any of the viral diseases, as 
they would be interrogated rather than counselled, if they had a disease (infectious) they were 
treated with a very obvious non touch technique, this disease seemed more contemptuous than 
their crime. People with HIV, hepatitis and TB reported to be treated very poorly by prison 
officers, as there was an abnormal fear of contracting the disease. One prisoner was advised 
not to have testing, as he would be incapable of reducing his risk factors.’ (19) 
‘One prisoner expressed his concerns about sterilisation of dental equipment between pa-
tients – was concerned re. Potential for transmission of blood borne viruses’ (13) 
‘Woman – shared razors!’ (17) 
‘Some prisoners were concerned that razors were being shared (17) 
‘Vaccination schedules were often incomplete, the prisoner unaware of how many should be 
administered and some had been vaccinated on multiple separate occasions – confusion and 
anxiety’ (5) 
 
 
 
26 
Results 
…………………………………………………………………………………..……………………………….. 
 
 
3.7.5 Needs of the psychologically vulnerable 
A few observations were made about both the treatments available to those with psychologi-
cal difficulties, and the appropriateness of the setting for disturbed individuals. An example of 
good practice was also identified: 
“2 disprin’ when feelings of anxiety/depression expressed” (14) 
‘Definite need for greater psychological services in Mountjoy. I saw on two occasions three 
prisoners in one cell, two kept the suicidal one ‘company’/Hardly the modern treatment, or 
have I missed something?’ (14) 
‘Some more articulate prisoners commented that mentally disturbed prisoners in ‘c’ wing of 
Mountjoy should be in hospital – having seen what they were talking about I agree’ (3) 
‘Cork – good psychiatric services – setting up cognitive skills course for ordinary prisoners 
(as well as sex offenders)’ (16) 
3.7.6 Organisational aspects of the prison medical services 
A number of the survey team commented on organisational aspects of the prison medical ser-
vice, and the variation in both access and standards that was evident from prison to prison. 
Observations varied from reporting the prisoners’ perceived difficulties with access to both 
primary and secondary care, to suggestions as to how the service could be improved. 
‘One or two said they had been denied drugs for illness which they had for 15-20 years’ (1) 
‘Difficulty seeing a doctor when required’ (14) 
‘Poor access to prison doctor’ (17) 
‘Many respondents said they were unhappy with the provision of health care given to hem i.e. 
length of time it took to see a doctor – very little time given to them by doctor. Many prisoners 
were started on hepatitis B vaccination programme did not know what they were getting.’ (18) 
‘They discussed issues relating to inadequate primary care and GP facilities in prison. The 
need for a more comprehensive primary care services and better follow up was emphasised.’ 
‘Limited access to health care, lack of privacy, assumption of malingering. As a result, delays 
in diagnosis, potentially damaging for the individual (and in the case of communicable dis-
ease – prisoners and staff and even relations)’ (9) 
‘Liver biopsy appointments cancelled (in one case 5 times) because no prison staff available 
to accompany prisoner to hospital’ (14) 
‘To a certain extent the present system seems to suit in that visits to hospital outpatients are 
welcomed by prisoners (day out) and prison officers (overtime, day out)’ (3) 
‘Under-resourced’ (3) 
‘Appears to run on an ad-hoc basis.’ (14) 
‘Vagueness about accountability, more explicit policies would help’ (3) 
‘Need more organised comprehensive primary care services and psychiatric services.’ (9) 
‘Need for one medical director in each prison who would be interested in screening for TB, 
blood borne viruses etc. on entrance to prison system – should not only be based on symp-
toms and GP issues’ (13) 
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3.7.7 General conditions in prison 
Three general issues in relation to living conditions in prison were raised: 
Food: ‘Portlaoise best food, Limerick food awful and not enough! (this was said by quite a 
few prisoners, especially those who worked out in the gym)’ (16) 
Hygiene: ‘Toilets blocked, dirty, concern expressed re infection risk’ (17) 
Activities: ‘The positive impact of the gym and education on health was mentioned’ (6) 
The happiest seeming person I met among the prisoners on the two occasions when I helped 
out was a young prisoner who ran exercise classes. And the prisoner seemed to have a good 
sense of their own worth which probably contributed to their general well-being. (Wording 
altered slightly to main confidentiality) (7) 
3.7.8 Summary 
Some examples of good care were identified but, in general, the comments point to shortcom-
ings with the existing prison health care services, highlighting deficiencies in access, attitude 
and quality. The fact that the health care service is integrated with the prison regime was iden-
tified as a potential barrier to good care. 
As people generally volunteer negative rather than positive views, these comments should be 
interpreted cautiously. 
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4 – Discussion 
4.1 Environment of prisons 
The organisation of health care within prisons presents greater challenges than the provision 
of comparable services outside prison. However, the very high response rate of prisoners in 
this study together with the excellent co-operation obtained by the research team from the 
prison staff at all levels augur well for future attempts to address the issues identified in this 
study. It is clear from the findings of the survey that Irish prisons vary significantly in their 
response to control of infection within them, to the extent of drug misuse, and to the preva-
lence of hepatitis B, hepatitis C and HIV among inmates. By and large prisons in Dublin have 
more drug use among the prison population and higher rates of infection. What is required is 
a tailor-made service for each prison within an overall framework of a co-ordinated response 
throughout the entire prison service. A broad consultative process will be required to identify 
the necessary changes and to bring them into effect. This consultative process will be most 
productive if it involves all the key stakeholders, including prisoners. 
4.2 Infections within prison 
There is a marked difference in the prevalence of the three viruses under investigation and, in 
common with studies in other countries, the prevalence of hepatitis C is by far the greatest. 
This finding is not surprising given the high proportion of prisoners who are drug users and 
the known high prevalence of hepatitis C in drug users in Ireland. Strategies to limit hepatitis 
C transmission outside prison need to be replicated inside prison and one of the cornerstones 
of this is methadone substitution treatment .The risk of hepatitis C increased with increasing 
time spent in prison. In the study there were 32 prisoners positive for antibodies to hepatitis C 
who reported never having injected drugs. A reduction in overcrowding should lessen the risk 
of infection by reducing the likelihood of risk behaviour. Hepatitis C was more common in 
young prisoners. This indicates that the health problems related to this infection will be an 
increasing feature in years to come. 
Hepatitis B infection was associated with drug use and with older age. This may be explained 
by the introduction of heroin to Dublin in the early 1980s with an associated increase in cases 
of hepatitis B infection in the early cohorts of injecting drug users. Later cohorts of drug users 
may have been protected to some extent by the provision of harm reduction programmes 
(methadone maintenance and needle exchange) and hepatitis B vaccination, all of which were 
introduced in the early 1990s. 
The very low prevalence of HIV in this study is consistent with data from outside prison 
which demonstrate a fall-off in the number of drug users presenting with HIV and AIDS in 
this country over the past 5 years. The predominant focus on HIV infection in the prison 
would seem to be somewhat misplaced, although HIV is always a cause of concern because 
of its high death rate. It should be stressed that the major public health issue identified in this 
study is hepatitis C. 
The mismatch between self-reported prevalence and laboratory results has important implica-
tions for education programmes within the prison service. Some prisoners are unaware that 
they have been infected and may continue to transmit the infection. 
Strategies employed outside prison to limit the transmission of these three viruses include the  
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provision of harm reduction services; these programmes need to be available on a wide scale 
within the prison service. The most appropriate methodology utilised to provide these ser-
vices in the prison setting requires discussion and consultation with the relevant stakeholders. 
This should be dealt with as a matter of urgency. 
4.3 Hepatitis B vaccination 
Hepatitis B vaccination is an effective preventive measure. Our findings suggest a very vari-
able uptake of vaccination. The written policy should be clearly displayed and available to 
doctors and prisoners. This should lead to increased vaccine uptake throughout the prison 
system. It is good medical practice outside prison to actively promote and provide hepatitis B 
vaccination to those groups who are at risk, and prisoners, whether they inject drugs or not, 
are regarded as a high risk group. Accordingly, a more active programme of vaccination needs 
to be put in place so that this highly effective preventive measure can be offered at every op-
portunity. For many drug users prison probably represents the best prospect of receiving hepa-
titis B vaccine. This opportunity should be taken in the interests of protecting individual pris-
oners and their families. 
4.4. Drug use in prison 
Apart from its impact on hepatitis B, hepatitis C and HIV, the drug issue in prison should be 
addressed in its own right. There is evidence from our survey of considerable drug use within 
Irish prisons, not confined to Dublin. There is also evidence of initiation into drug use within 
prison and of sharing of drug injection equipment within prison. Sharing of equipment within 
prison is more common than the sharing engaged in prior to committal. It is likely that some 
prisons will continue to inject and share injecting equipment while in prison and for these a 
supply of clean needles will lessen the risk of virus transmission. We appreciate that this is a 
contentious issue and raises justifiable concerns among staff. These concerns will need to be 
addressed in any proposed changes of policy and practice. 
One third of drug users were on a methadone programme prior to imprisonment. Prisoners are 
rarely maintained on methadone in prison. If a greater proportion of drug users were offered 
methadone maintenance in prison, this would have the effect of lessening risk of viral trans-
mission. This is a matter of some urgency. 
The provision of such harm reduction strategies in prison can be contentious. However, a 
need has been identified and the case for the provision of these services within some prisons 
in Ireland is compelling. 
4.5 Young prisoners 
Almost 15% of the prisoners in the study were aged under 20 years. The greatest prevalence 
of hepatitis C infection was in the 20-24 age group. Interventions specifically targeted at 
teenage prisoners offer the best prospect of preventing acquisition of hepatitis C infection. 
4.6 Sexual risk factors 
We have found evidence of sexual contact between men in prison and an association between 
both hepatitis B and HIV infection and sex between men. This sexual activity needs to be ac-
knowledged and preventive measures, such as education of prisoners and the provision of 
condoms, should be put in place. 
4.7 Prison health service 
The results of the qualitative component of the study raise concerns about the provision of 
medical care in prisons. Comments to the study team during the course of our fieldwork indi-
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cated that there is a problem with confidentiality and with differing attitudes among prison 
doctors. The Department of Justice, Equality and Law Reform should ensure that the prison 
medical service is provided by staff who are committal to the policies that have been agreed. 
Equally, health professional staff require administrative and management support to encour-
age and maintain professional commitment to the provision of a quality health service for 
prisoners. This health service for prisoners should be seen to be separate from the custodial 
service. In our opinion, the best way to ensure this is to transfer responsibility for the prison 
health service from the Department of Justice, Equality and Law Reform to the Department of 
Health and Children. 
4.8 Oral fluid 
This study has demonstrated that the use of oral fluid as opposed to blood for antibody detec-
tion is feasible and easy to carry out. This method of antibody testing could be extended for 
use outside the prison population if a facility for laboratory analysis in Ireland can be ar-
ranged. 
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5 – Recommendations 
We believe that major changes are needed in the organisation and delivery of the prison health 
service. As previously stated, this will best be achieved through a wide consultative process. 
As a contribution to this process, we present our recommendations. These are presented as (i) 
topic-specific and (ii) organisational recommendations. 
5.1 Topic-specific recommendations 
5.1.1 Infectious disease control 
All prisoners, regardless of duration of sentence, should be offered hepatitis B vaccination on 
committal to prison, with the exception of those having documented evidence of immunity. 
For short term prisoners, accelerated vaccination should be offered. 
In the event of a prisoner being released before completion of a course of vaccination, the 
prisoner should received the remaining doses through their general practitioner or in an alter-
native setting such as a health board clinic. Currently non-drug using ex-prisoners are not 
classified as high risk, so special arrangements would need to be made so that they can re-
ceive the service free of charge. 
All prisoners should have the opportunity to request testing for hepatitis B, hepatitis C and 
HIV directly from the prison doctor, with assurances of confidentiality of both request and 
result. 
The possibility of carrying out viral antibody testing by analysis of oral fluid rather than 
blood should be pursued. As the sensitivity of the hepatitis C test is only 80%, an additional 
more sensitive test may be required for those with negative oral fluid results. 
Cases of hepatitis B and hepatitis C identified in prisoners should be notified to the relevant 
Director of Public Health (Medical Officer of Health) as per the Infectious Disease Regula-
tions, 1981. 
Details of cases of HIV should be reported to the relevant regional AIDS co-ordinator as per 
Department of Health guidelines. 
An annual survey should be carried out on a random sample of prisoners to monitor trends in 
hepatitis C infection. 
Prison authorities should ensure, as far as possible, that there is no sharing of razors or 
toothbrushes. 
5.1.2 Drug services 
All prisoners should have the option of being accommodated in a drug free prison unit. Such 
facilities should be available as a priority to young offenders 
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An individualised drug treatment and rehabilitation plan should be offered to all prisoners 
who are addicted to opiates. This should take account of the social, educational and medical 
needs of the prisoners and consequently will require multi-disciplinary input. Existing pro-
grammes in some prisons will provide a good basis for this. 
Prisoners entering prison on a methadone programme should have that programme continued. 
Details of prisoners on methadone should be reported to the central (methadone) treatment list 
as per the Misuse of Drugs Act (1998 Regulations). 
Any future methadone programmes in prison should be evaluated. 
It is acknowledged that needle exchange in prison is a controversial issue which causes con-
cerns among prison staff. Notwithstanding this, a strictly controlled supply of clean needles 
and syringes should be available for those prisoners who will continue to inject opiates. 
A mechanism for the disposal of used needles and syringes should be provided. 
Qualitative research should be carried out to: 
i. examine changes in sharing practices among injecting drug users before and during 
imprisonment. 
ii. determine the extent of knowledge among prisoners, and in particular non drug users, 
of hepatitis B, hepatitis C and HIV. 
5.1.3 Sexual spread of infection 
Condoms should available free of charge to all prisoners. 
5.1.4 Education and training 
A structured education programme, covering the topics of drug use, blood-borne infections 
and safe sex, should be offered on an ongoing basis to all prisoners and staff. Excellent exam-
ples of such programmes already exist in some prisons. 
Further training on a range of health topics should be offered to those prison officers who 
wish it. 
The results of this study should be made available in summary form to all prisoners and 
prison officers. 
5.2 Organisational recommendations 
In light of the identified health needs of prisoners, a prison drug service and a prison infection 
service should be set up, with identified responsibility, within an overall restructured prison 
health service. 
The control of communicable disease is a public health function. A public health specialist(s) 
should have responsibility for this function in prisons. 
Individual medical care for prisoners should be improved by the provision of a more compre-
hensive and accessible service, with a greater input of general practitioner time, supported by 
nurses who have either public health or practice nurse training. 
Prison medical records should be held on networked computers to allow for ease of access 
and retrieval by prison doctors in other prisons. This would include the recording of viral an-
tibody test results and vaccination status Confidentiality of records would have to be pro-
tected in such a system, with controlled access. 
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Pending a restructuring of the existing service, confusion about accountability and managerial 
responsibility in the prison medical service needs to be resolved as matter of the utmost ur-
gency. 
Uniform prison health policies for the control of communicable disease, including hepatitis B, 
hepatitis C and HIV, should be drawn up and disseminated within the prison service. A 
mechanism should be put in place to ensure that these policies are implemented. 
Regular audit should be carried out on the prison health care service to allow for continuous 
improvement. 
Where any new service is introduced a formal evaluation should be carried out after an ap-
propriate period of time. 
Only health professionals committed to working in a newly restructured prison health service 
should be employed. Consideration should be given to employing doctors with a primary 
commitment to the prison medical service rather than practice in the community, particularly 
in Mountjoy Prison. 
The problem of overcrowding should be addressed as a matter of urgency, with particular at-
tention to providing facilities for young offenders. 
The potential for rehabilitation and quality health care to be provided on a much wider scale 
than heretofore in the prison system should be realised. 
The goal of providing a health service for prisoners which is comparable to that outside 
prison is an ambitious one; it would be better served in our opinion if ultimate responsibility 
for the prison health service rested with the Department of Health and Children. 
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Appendix 1 – Request for Proposal 
 
 
 
Department of Justice, Equality and Law Reform 
PRISONS DIVISION RESEARCH PROGRAMME 
REQUEST FOR PROPOSAL (RFP) 
___________________________________________________ 
2. LEVEL OF HIV AND HEPATITIS INFECTION AMONG PRISONER POPULATION 
1 Background 
The Department of Justice, Equality and Law Reform is embarking on a research programme in rela-
tion to various matters within its area of responsibility. Several of these matters fall under the remit 
of the Prisons Division. Prisons Division has responsibility for the provision and maintenance of a 
secure, efficient and progressive system of containment and rehabilitation for offenders committed to 
custody. The Division aims to treat offenders while in custody with care, justice, dignity and respect 
with particular emphasis on health, education, training and offender welfare. 
2 Project 
In this context, the Prisons Division is seeking to establish levels of HIV and Hepatitis infection 
among the prisoner population. The project involves 
♦ 
♦ 
♦ 
♦ 
♦ 
♦ 
♦ 
♦ 
the design of an appropriate anonymous questionnaire; 
the organisation of the completion of this questionnaire across a wide representative  
sample of the prisoner population; 
the organisation of a complimentary programme of saliva testing; 
the compilation of the results of the questionnaire; and 
the study of those results and the production of a finished report on the findings. 
Accordingly the Department hereby invites proposals for the provision of the above service. 
Proposals should include 
a detailed outline of the methodology 
timescale; and 
total cost of the research exercise 
 
INVITATION TO TENDER 
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Appendix 2 – Survey team 
Dr Shane Allwright Senior Lecturer in Epidemiology* 
Dr Joseph Barry Public Health Doctor* 
Dr Geira Baruda Medical Doctor* 
Dr Fiona Bradley General Practitioner* 
Ms Marlen Carvalho Research Associate* 
Dr Tara Conlon General Practitioner 
Mr Derek Duggan 4th year Dental Student 
Dr Emer Feely Public Health Doctor 
Mr Killian Forde ENN administrator* 
Ms Carrie Garavan Research Nurse, MPH 
Ms Anne Halpin Laboratory Technician, M.Sc.* 
Ms Deirdre Handy Executive Officer* 
Dr Derval Igoe Public Health Doctor 
Ms Jean Long Research Nurse, M.Sc.* 
Dr Frank Lule Medical Doctor* 
Ms Geraldine McCullough Research Nurse, M.Sc.* 
Dr Paul McKeon Public health Doctor 
Ms Mary McSweeney Research Associate* 
Ms Ailbhe Mealy Executive Officer* 
Ms Louise Mullen Psychologist, M.Sc.* 
Dr Joan O’Donnell Public Health Doctor 
Prof Tom O’Dowd General Practitioner* 
Dr Jill O’Leary Public Health Doctor 
Ms Hilda O’Neill Research Nurse, M.Sc.* 
Dr Patrick O’Sullivan Public Health Doctor 
Ms Sheilagh Reaper-Reynolds Education Officer 
Ms Eimear Simms Environmental Health Officer, M.Sc.* 
Dr Lelia Thornton Public Health Doctor 
Dr Aregay Weldegebriel Medical Doctor* 
 
 
*affiliated with the Department of Community Health and General Practice, Trinity College Dublin. 
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Appendix 3a – Questionnaire for 
male respondents 
 
  
 DEPARTMENT OF COMMUNITY HEALTH 
 AND GENERAL PRACTICE, TCD 
ANONYMOUS HIV & HEPATITIS SURVEY IN IRISH PRISONS 
1 What age you? (in years) __________  
PLEASE ANSWER BY FILLING IN THE CIRCLES LIKE THIS .................... o 
2 How long is your prison sentence from beginning to end? 
Remand...........................................................  o 
3 months or less ..............................................  o 
More than 3 months but less than 12 months..  o 
1 to 3 years......................................................  o 
More than 3 years............................................  o 
3 How long have you been in prison on this sentence/remand? 
3 months or less ..............................................  o 
More than 3 months but less than 12 months..  o 
1 to 3 years......................................................  o 
More than 3 years............................................  o 
4 Approximately how much of the last 10 years have you spent in 
prison (including this sentence or remand)? 
3 months or less ..............................................  o 
More than 3 months but less than 12 months..  o 
1 to 3 years......................................................  o 
More than 3 years............................................  o 
5 In the last year have you smoked (chased) heroin? 
Yes ........................  o 
No ........................  o 
6 Have you EVER INJECTED drugs? 
Yes ........................  o 
No ........................  o 
If YES, please turn to next page 
If NO, please go to Question 14* on Page 3   
1 
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7 How old were you when you first injected drugs? ________ 
 (in years) 
8 Were you in prison the FIRST time you ever injected? 
Yes ........................  o 
No ........................  o 
9 BEFORE coming into prison, when was the last time you injected? 
On the day you came into prison  ...................  o 
In the week before  .........................................  o 
In the month before  .......................................  o 
In the year before  ..........................................  o 
More then 1 year before  ................................  o 
Does not apply to me  ....................................  o 
10 In the month BEFORE coming into prison, had you shared any of 
these works with someone else: 
- needles (spikes)? Yes ........................  o 
 No ........................  o 
- syringes (barrels)? Yes ........................  o 
 No ........................  o 
- others? Yes ........................  o 
- (filters, spoons etc.) No ........................  o 
11 Were you on a methadone programme at the time of committal? 
Yes ........................  o 
No ........................  o 
12 While IN PRISON, have you ever shared any of these works with 
someone else 
- needles (spikes)? Yes ........................  o 
 No ........................  o 
- syringes (barrels)? Yes ........................  o 
 No ........................  o 
- others? Yes ........................  o 
(filters, spoons etc.) No ........................  o 
13 How many times have you injected in the  ________  
 last month? 
2 
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HALF WAY THERE!!! 
 
14* In the 12 months before coming into prison, did you have sexual 
intercourse with women? 
Yes ........................  o 
No ........................  o 
If yes, did you use condoms? 
Always/Sometimes .........  o 
Never  ........................  o 
15 Did you EVER have anal sex with another man? 
Yes ........................  o 
No ........................  o 
If yes, did you use condoms? 
Always/Sometimes .........  o 
Never  ........................  o 
16 Have you had anal sex while in prison? 
Yes ........................  o 
No ........................  o 
17 Have you ever been treated for an STD? (sexually transmitted disease) 
Yes ........................  o 
No ........................  o 
18 Have you ever had a blood test for HIV 
Yes ........................  o 
No ........................  o 
Don’t know .........  o 
If yes, what was the result? 
Positive (infected) .........  o 
Negative (not infected) .........  o 
Don’t know ........................  o 
Please turn to last page    
3 
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19 Have you ever had a blood test for hepatitis B? 
Yes ...............................  o 
No ...............................  o 
Don’t know ....................  o 
If yes, what was the result? 
Positive (infected) .............  o 
Positive (not infected) ........  o 
Don’t know ........................  o 
20 Have you been vaccinated against hepatitis B? 
Yes ...............................  o 
No ...............................  o 
Don’t know ....................  o 
If yes, were you vaccinated in prison? 
Yes ...............................  o 
No ...............................  o 
If vaccinated, have you had the complete 
Course of 3 injections? 
Yes ...............................  o 
No ...............................  o 
Don’t know ....................  o 
21 Have you ever had a blood test for hepatitis C? 
Yes ...............................  o 
No ...............................  o 
Don’t know ....................  o 
If yes, what was the result? 
Positive (infected) .............  o 
Positive (not infected) ........  o 
Don’t know ........................  o 
THANKS FOR TAKING PART  
PLEASE PUT THE SALIVA AND QUESTIONNAIRE 
IN THE ENVELOPE  
4 
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Appendix 3b – Questionnaire for 
female respondents 
 
  
 DEPARTMENT OF COMMUNITY HEALTH 
 AND GENERAL PRACTICE, TCD 
ANONYMOUS HIV & HEPATITIS SURVEY IN IRISH PRISONS 
1 What age you? (in years) __________  
PLEASE ANSWER BY FILLING IN THE CIRCLES LIKE THIS .................... o 
2 How long is your prison sentence from beginning to end? 
Remand...........................................................  o 
3 months or less ..............................................  o 
More than 3 months but less than 12 months..  o 
1 to 3 years......................................................  o 
More than 3 years............................................  o 
3 How long have you been in prison on this sentence/remand? 
3 months or less ..............................................  o 
More than 3 months but less than 12 months..  o 
1 to 3 years......................................................  o 
More than 3 years............................................  o 
4 Approximately how much of the last 10 years have you spent in 
prison (including this sentence or remand)? 
3 months or less ..............................................  o 
More than 3 months but less than 12 months..  o 
1 to 3 years......................................................  o 
More than 3 years............................................  o 
5 In the last year have you smoked (chased) heroin? 
Yes ........................  o 
No ........................  o 
6 Have you EVER INJECTED drugs? 
Yes ........................  o 
No ........................  o 
If YES, please turn to next page 
If NO, please go to Question 14* on Page 3   
1 
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7 How old were you when you first injected drugs? ________ 
 (in years) 
8 Were you in prison the FIRST time you ever injected? 
Yes ........................  o 
No ........................  o 
9 BEFORE coming into prison, when was the last time you injected? 
On the day you came into prison  ...................  o 
In the week before  .........................................  o 
In the month before  .......................................  o 
In the year before  ..........................................  o 
More then 1 year before  ................................  o 
Does not apply to me  ....................................  o 
10 In the month BEFORE coming into prison, had you shared any of 
these works with someone else: 
- needles (spikes)? Yes ........................  o 
 No ........................  o 
- syringes (barrels)? Yes ........................  o 
 No ........................  o 
- others? Yes ........................  o 
(filters, spoons etc.) No ........................  o 
11 Were you on a methadone programme at the time of committal? 
Yes ........................  o 
No ........................  o 
12 While IN PRISON, have you ever shared any of these works with 
someone else 
- needles (spikes)? Yes ........................  o 
 No ........................  o 
- syringes (barrels)? Yes ........................  o 
 No ........................  o 
- others? Yes ........................  o 
(filters, spoons etc.) No ........................  o 
13 How many times have you injected in the  ________  
 last month? 
2 
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HALF WAY THERE!!! 
 
14* In the 12 months before coming into prison, did you have sexual 
intercourse with men? 
Yes ........................  o 
No ........................  o 
If yes, did you use condoms? 
Always/Sometimes .........  o 
Never  ........................  o 
15 Have you ever been treated for an STD? 
 (sexually transmitted disease) 
Yes ........................  o 
No ........................  o 
16 Have you ever had a blood test for HIV 
Yes ........................  o 
No ........................  o 
Don’t know .........  o 
If yes, what was the result? 
Positive (infected) .........  o 
Negative (not infected) .........  o 
Don’t know ........................  o 
Please turn to last page    
3 
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17 Have you ever had a blood test for hepatitis B? 
Yes ...............................  o 
No ...............................  o 
Don’t know ....................  o 
If yes, what was the result? 
Positive (infected) .............  o 
Positive (not infected) ........  o 
Don’t know ........................  o 
18 Have you been vaccinated against hepatitis B? 
Yes ...............................  o 
No ...............................  o 
Don’t know ....................  o 
If yes, were you vaccinated in prison? 
Yes ...............................  o 
No ...............................  o 
If vaccinated, have you had the complete 
Course of 3 injections? 
Yes ...............................  o 
No ...............................  o 
Don’t know ....................  o 
19 Have you ever had a blood test for hepatitis C? 
Yes ...............................  o 
No ...............................  o 
Don’t know ....................  o 
If yes, what was the result? 
Positive (infected) .............  o 
Positive (not infected) ........  o 
Don’t know ........................  o 
THANKS FOR TAKING PART  
PLEASE PUT THE SALIVA AND QUESTIONNAIRE 
IN THE ENVELOPE  
4 
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Appendix 4 – Laboratory analysis of 
Oral fluid specimens 
Each oral fluid specimen was tested for total IgG (to check specimen quality), anti-HIV, anti-
HBc and anti-HCV antibodies. 
• Anti-HIV testing was done using the Murex 1 + 2 GACELIASA (VK61,33-34 Abbott 
Diagnostics, Maidenhead, UK), according to the manufacturer’s instructions, with 
positives confirmed using a modified protocol for the Clonesystems Detect-HIV FIA 
(Biostat Diagnostics, Stockport, UK). 
• Anti-HBc testing used Murex HBc ICE (Abbott Diagnostics, Maidenhead, UK), with 
positives confirmed with an ‘in-house’ RIA.35 
• Anti-HCV antibodies were sought employing a modified protocol for the Ortho HCV 
3.0 SAVe ELISA (Product number 940982, Ortho Diagnostics, Amersham, UK). Bor-
derline reactives (OD/CO 0.8 – 3.0) were further investigated using a modified Chiron 
RIB. HCV 3.0 (Product number 930780, Ortho Diagnostics, Amersham, UK). 
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Appendix 5 Frequency distribution of questionnaire 
responses by prison type (medium and 
 high risk) and injecting drug use. 
Demographics and prison history 
Variable   Outcome All
n (%) 
High 
n (%) 
Medium 
n (%) 
IDU 
n (%) 
Non IDU 
n (%) 
Age in years 16-17 
18-19 
20-24 
25-29 
30-34 
35-44 
45-54 
55-64 
65+ 
n 
40 (3.5) 
137 (11.9) 
369 (32.1) 
255 (22.2) 
151 (13.2) 
135 (11.8) 
45 (3.9) 
14 (1.2) 
1 (0.9) 
1147 (100) 
28 (4.1) 
94 (13.8) 
219 (32.2) 
145 (21.3) 
91 (13.4) 
78 (1.5) 
17 (2.5) 
7 (1) 
1 (0.2) 
680 (100) 
12 (2.6) 
43 (9.2) 
150 (32.1) 
110 (23.6) 
60 (12.8) 
57 (12.2) 
28 (6) 
7 (1.5) 
0 
467 (100) 
10 (2) 
59 (12.1) 
192 (39.3) 
123 (25.1) 
63 (12.9) 
39 (8) 
2 (0.4) 
1 (0.2) 
0 
489 (100) 
29 (4.5) 
77 (11.9) 
170 (26.3) 
130 (20.1) 
87 (13.5) 
95 (14.7) 
43 (6.6) 
13 (2) 
1 (0.2) 
645 (100) 
Gender  Male
Female 
n 
1148 (95.2) 
57 (4.7) 
1205 (100) 
S667 (93) 
50 (7) 
717 (100) 
481 (98.6) 
7 (1.4) 
488 (100) 
480 (93.4) 
34 (6.6) 
514 (100) 
651 (96.6) 
23 (3.4) 
674 (100) 
Length of prison 
sentence 
Remain 
3 months or less 
>3-<12 months 
1-3 
>3 years 
n 
157 (13.1) 
60 (5) 
213 (17.8) 
308 (25.8) 
458 (38.3) 
1196 (100) 
120 (16.9) 
29 (4.1) 
111 (15.6) 
170 (23.9) 
281 (39.5) 
711 (100) 
37 (7.6) 
31 (6.4) 
102 (21) 
138 (28.5) 
177 (36.5) 
485 (100) 
65 (12.7) 
18 (3.5) 
66 (12.9) 
124 (24.3) 
238 (46.6) 
511 (100) 
92 (13.7) 
40 (5.9) 
144 (21.4) 
179 (26.6) 
218 (32.4) 
673 (100) 
Length in prison on 
this sentence 
3 months or less 
>3<12 months 
1-3 years 
>years 
n 
319 (27) 
392 (33.2) 
319 (27) 
151 (12.8) 
1181 (100) 
201 (28.5) 
223 (31.6) 
195 (27.7) 
86 (12.2) 
705 (100) 
118 (24.8) 
169 (35.5) 
124 (26) 
65 (13.7) 
476 (100) 
119 (23.3) 
154 (30.2) 
164 (32.2) 
73 (14.3) 
510 (100) 
198 (30) 
232 (35.2) 
152 (23) 
78 (11.8) 
660 (100) 
Time during the last 
10 yr. Spent in prison 
3 months or less 
>3<12 months 
1-3 years 
>3years 
n 
137 (11.6) 
197 (16.7) 
300 (25.4) 
546 (46.3) 
1180 (100) 
87 (12.3) 
103 (14.6) 
167 (23.7) 
349 (49.4) 
706 (100) 
50 (10.5) 
94 (19.8) 
133 (28.1) 
197 (41.6) 
474 (100) 
40 (7.8) 
49 (9.6) 
121 (23.7) 
300 (58.8) 
510 (100) 
97 (14.7) 
146 (22.1) 
175 (26.5) 
242 (36.7) 
660 (100) 
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Drug use 
Variable   Outcome All
n (%) 
High 
n (%) 
Medium 
n (%) 
IDU 
n (%) 
Non IDU 
n (%) 
Smoked heroin in the 
last 12 months 
Yes 
No 
n 
545 (45.9) 
642 (54.1) 
1187 (100 
408 (57.4) 
303 (42.6) 
711 
137 (28.8) 
339 (71.2) 
476 
420 (82.5) 
89 (17.5) 
509 (100) 
121 (18.1) 
549 (81.9) 
670 (100) 
Every injected drugs Yes 
No 
n 
514 (43.2) 
674 (56.7) 
1188 (100) 
414 (58.2) 
297 (41.8) 
712 (100 
100 (21) 
377 (79) 
477 (100) 
514 (100) 
 
 
 
674 (100) 
 
Age when first injected 
drugs 
11-13 
14-15 
16-17 
18-19 
20-24 
25-29 
30-38 
n 
25 (5) 
97 (19.6) 
144 (29) 
93 (18) 
91 (1.4) 
31 (6.3) 
(2.8) 
495 (100) 
22 (5.4) 
78(19.3) 
118 (29.2) 
79 (19.5) 
68 (16.8) 
28 (6.9) 
11 (2.7) 
404 (100) 
3 (3.3) 
19 (20.9) 
26 (28.6) 
14 (15.4) 
23 (25.3) 
3 (3.3) 
3 (3.3) 
91 (100) 
25 (5) 
97 (19.6) 
144 (29) 
93 (18.8) 
91 (18.4) 
31 (6.3) 
14 (2.8) 
495 (100) 
0 
 
 
No. of years since first 
injection 
<3 years 
3-12 yrs 
6-8 yrs 
9-14 yrs 
15+ 
85 (18) 
153 (32.3) 
110 (23.2) 
72 (15.2) 
53 (11.2) 
473 (100) 
68 (17.7) 
127 (33) 
98 (25.4) 
55 (14.3) 
37 (9.6) 
385 (100) 
17 (19.3) 
26 (29.5) 
12 (13.6) 
17 (19.3) 
16 (18.2) 
88 (100) 
85 (18) 
153 (32.3) 
110 (23.2) 
72 (15.2) 
53 (11.2) 
473 (100) 
0 
 
 
Last time injected before 
coming into prison 
On the day committed 
In the week before 
In the month before 
In the year before 
More than one year 
before 
n 
n 
261 (52.3) 
86 (17.2) 
34 (6.8) 
43 (8.6) 
43 (8.6) 
 
32.6.4 
499 (100) 
220 (54) 
69 (1.9) 
29 (7.1) 
30 (7.4) 
35 (8.6) 
 
24 (5.9) 
407 (100) 
41 (44) 
17 (18.3) 
5 (5.4) 
13 (14) 
8 (8.6) 
 
9 (9.7) 
93 (100) 
261 (52.3) 
86 (17.2) 
34 (6.8) 
43 (8.6) 
43 (8.6) 
 
32 (6.4) 
499 (100) 
0 
 
 
Started injecting in 
prison 
Yes 
No 
n 
104 (20.5) 
402 (79.5) 
506 (100) 
82 (20) 
329 (80) 
412 (100) 
22 (23.2) 
73 (76.8) 
95 (100) 
104 (205) 
402 (79.5) 
506 (100) 
0 
 
 
On methadone prior to 
committal 
Yes 
No 
n 
187 (37.3) 
315 (62.7) 
502 (100) 
156 (38.3) 
253 (61.7) 
409 (100) 
31 (33.3) 
62 (66.7) 
93 (100) 
187 (37.3) 
315 (62.7) 
502 (100) 
0 
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Sharing equipment among injecting drug users 
Variable   Outcome All
n (%) 
High 
n (%) 
Medium 
n (%) 
IDU 
n (%) 
Non IDU 
n (%) 
Sharing before        
Needles  Yes
No 
n 
225 (46) 
264 (54) 
489 (100) 
184 (46.1) 
215 (53.8) 
399 (100) 
41 (45.6) 
49 (54.4) 
90 (100) 
225 (46) 
264 (54) 
489 (100) 
0 
Syringes  Yes
No 
n 
232 (51.4) 
219 (48.6) 
451 (100) 
192 (51.9) 
178 (48.1) 
370 (100) 
40 (49.4) 
41 (50.6) 
81 (100) 
232 (51.4) 
219 (48.6) 
451 
0 
Filters and spoons etc 
 
Yes 
No 
n 
263 (58.6) 
186 (41.4) 
449 (100) 
220 (60) 
147 (40) 
367 (100) 
43 (52.4) 
39 (47.6) 
82 
263 (58.6) 
186 (41.4) 
449 (100) 
0 
Share before All 
Some 
Zero 
175 (36.6) 
140 (29.3) 
163 (34.1) 
478 (100) 
144 (36.9) 
117 (30) 
179 (33.1) 
390 (100) 
31 (35.2) 
23 (26.1) 
34 (38.6) 
88 (100) 
175 *36.6) 
140 (29.3) 
163 (34.1) 
478 (100) 
 
Sharing inside        
Needles  Yes
No 
n 
351 (70.6) 
146 (29.4) 
497 (100) 
295 (72.5) 
112 (27.5) 
407 (100) 
56 (62.2) 
34 (37.8) 
90 (100) 
351 (70.6) 
146 (29.4) 
497 (100) 
0 
Syringes  Yes
No 
n 
335 (72.2) 
129 (27.8) 
464 (100) 
283 (73.9) 
100 (26.1) 
383 (100) 
52 (64.2) 
29 (35.8) 
81 (100) 
334 (72.1) 
129 (27.9) 
463 (100) 
0 
Filters and spoons etc. Yes 
No 
n 
304 (67.4) 
147 (32.6) 
451 (100) 
255 (68.7) 
116 (31.3) 
371 (100) 
49 (61.2) 
31 (38.8) 
80 (100) 
304 (67.4) 
147 (32.6) 
451 (100) 
0 
Share in All 
Some 
Zero 
285 (58) 
86 (17.5) 
120 (24.4) 
491 (100) 
241 (59.8) 
68 (17.1) 
93 (23.1) 
403 (100) 
44 (49.4) 
18 (20.2) 
27 (30.3) 
89 (100) 
285 (58) 
86 (17.5) 
120 (24.4) 
491 (100) 
 
Times injected in the 
last month 
0 
1-19 
20+ 
n 
221 (50.5) 
141 (32.2) 
76 (7.3) 
438 (100) 
154 (42.9) 
133 (37) 
72 (20.1) 
359 (100) 
67 (84.8) 
8 (10.1) 
4 (5.1) 
89 (100) 
221 (50.5) 
141 (32.2) 
76 (17.3) 
438 (100) 
0 
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Sexual practices and precautions 
Variable   Outcome All
n (%) 
High 
n (%) 
Medium 
n (%) 
IDU 
n (%) 
Non IDU 
n (%) 
Sexual intercourse 
with the opposite 
gender in the 12 
months prior to 
committal 
Yes 
No 
N 
 
 
1088 (92) 
94 (8) 
1182 (100) 
 
 
662 (93.1) 
49 (6.9) 
711 (100) 
 
 
426 (90.4) 
45 (9.6) 
471 (100) 
 
 
483 (94.5) 
28 (5.5) 
511 (100) 
 
 
596 (90.2) 
65 (9.8) 
661 (100) 
 
 
Use condoms during 
heterosexual 
intercourse 
Yes 
No 
n 
347 (33.8) 
679 (66.2) 
1026 (100) 
211 (33.9) 
412 (66.1) 
623 (100) 
136 (33.7) 
267 (66.2) 
403 (100) 
138 (30.6) 
313 (69.4) 
451 (100) 
205 (36.2) 
361 (63.8) 
566 (100) 
Men ever have anal 
sex with men  
Yes 
No 
n 
28 (2.5) 
1088 (97.5) 
1116 (100) 
14 (2.1) 
639 (97.9) 
653 (100) 
14 (3) 
449 (97) 
463 (100) 
15 (3.4) 
459 (96.6) 
474 (100) 
12 (1.9) 
621 (98.1) 
633 (100) 
Use condoms during 
male homosexual 
intercourse 
Yes 
No 
n 
4 (19) 
17 (81) 
21 (100) 
3 (27.3) 
8 (72.7) 
11 (100) 
1 (10) 
9 (90) 
10 (100) 
1 (7.1) 
13 (92.9) 
14 (100) 
3 (42.9) 
4 (57.1) 
7 (100) 
Men ever have anal 
sex with men in 
prison 
Yes 
No 
n 
20 (1.8) 
1067 (98.2) 
1087 (100) 
7 (1.1) 
629 (98.9) 
636 (100) 
13 (2.9) 
438 (97.1) 
451 (100) 
9 (2) 
455 (98) 
464 (100) 
10 (1.6) 
605 (98.5) 
613 (100) 
Ever treated for STD Yes 
No 
n 
147 (12.6) 
1018 (87.4) 
1165 (100) 
103 (14.6) 
600 (85.4) 
703 (100) 
44 (9.5) 
418 (90.5) 
462 (100) 
87 (17.3) 
416 (82.7) 
503 (100) 
60 (9.2) 
593 (90.8) 
653 (100) 
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Reported blood test results and vaccination coverage 
Variable   Outcome All
n (%) 
High 
n (%) 
Medium 
n (%) 
IDU 
n (%) 
Non IDU 
n (%) 
Ever have a blood test 
for HIV 
Yes 
No 
Don’t know 
n 
449 (37.8) 
703 (59.3) 
34 (2.9) 
1186 (100) 
328 (46.2) 
366 (51.5) 
16 (2.2) 
710 (100) 
121 (25.4) 
337 (70.8) 
18 (3.8) 
476 (100) 
332 (65) 
172 (33.6) 
7 (1.4) 
511 (100) 
116 (17.4) 
524 (78.8) 
25 (3.8) 
665 (100) 
Reported HIV result 
 
Yes 
No 
Don’t know 
n 
20 (4.5) 
370 (83.5) 
53 (12) 
443 (100) 
16 (4.9) 
269 (82.8) 
40 (12.3) 
325 (100) 
4 (3.4) 
101 (85.6) 
13 (11) 
118 (100) 
18 (5.5) 
274 (83.8) 
35 (10.7) 
327 (100) 
2 (1.7) 
95 (82.6) 
18 (15.7) 
115 (100) 
Ever have a blood test 
for hepatitis B 
Yes 
No 
Don’t know 
n 
335 (28.5) 
773 (65.7) 
69 (5.9) 
1177 (100) 
260 (36.8) 
411 (58.1) 
36 (5.1) 
707 (100) 
75 (16) 
362 (77) 
33 (7) 
470 (100) 
252 (49.6) 
231 (45.5) 
25 (4.9) 
508 (100) 
83 (12.6) 
534 (80.9) 
43 (6.5) 
660 (100) 
Reported hepatitis B 
result 
Yes 
No 
Don’t know 
n 
63 (19.6) 
209 (64.9) 
50 (15.5) 
322 (100) 
48 (19.2) 
164 (65.6) 
38 (15.2) 
250 (100) 
15 (20.8) 
45 (62.5) 
12 (1.7) 
72 (100) 
58 (24) 
152 (62.8) 
32 (13.2) 
242 (100) 
5 (6.3) 
57 (71.2) 
18 (22.5) 
80 (100) 
Ever have a blood test 
for hepatitis C 
Yes 
No 
Don’t know 
n 
348 (29.9) 
725 (62.3) 
91 (7.8) 
1164 (100) 
278 (39.6) 
382 (54.4) 
42 (6) 
702 (100) 
70 (15.2) 
343 (74.2) 
49 (10.6) 
462 (100) 
302 (59.3) 
188 (36.9) 
19 (3.7) 
509 (100) 
46 (7.1) 
530 (81.9) 
71 (11) 
646 (100) 
Reported hepatitis C 
result 
Yes 
No 
Don’t know 
n 
232 (67.8) 
76 (22.2) 
34 (9.9) 
342 (100) 
189 (69.5) 
56 (20.6) 
27 (9.9) 
272 (100) 
43 (61.4) 
20 (25.6) 
7 (10) 
70 (100) 
229 (76.6) 
44 (14.7) 
26 (8.7) 
299 (100) 
3 (7) 
32 (74.4) 
8 (18.6) 
43 (16) 
Vaccinated against 
hepatitis B 
Yes 
No 
Don’t know 
n 
504 (43.5) 
547 (47.1) 
109 (9.4) 
1160 (100) 
381 (54.7) 
272 (39) 
44 (6.3) 
697 (100) 
123 (26.6) 
275 (59.4) 
65 (14) 
463 (100) 
300 (59.6) 
180 (35.8) 
23 (4.6) 
503 (100) 
202 (31.2) 
361 (55.7) 
85 (13.1) 
648 (100) 
Vaccinated in prison Yes 
No 
n 
446 (90.8) 
45 (9.2) 
491 (100) 
334 (90.5) 
35 (5) 
369 (100) 
112 (91.8) 
10 (8.2) 
122 (100) 
266 (91.1) 
26 (8.9) 
292 (100) 
179 (90.9) 
18 (9.1) 
197 (100) 
Complete 3 doses of 
hepatitis vaccine 
Yes 
No 
Don’t know 
n 
304 (60.4) 
180 (35.8) 
19 (3.8) 
503 (100) 
230 (61.2) 
132 (35.1) 
14 (3.7) 
376 (100) 
74 (58.3) 
48 (37.8) 
5 (3.9) 
128 (100) 
184 (61.7) 
101 (33.9) 
13 (4.4) 
298 (100) 
118 (58) 
79 (39) 
6 (3) 
203 (100) 
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Oral fluid test results 
Variable   Outcome All
n (%) 
High 
n (%) 
Medium 
n (%) 
IDU 
n (%) 
Non IDU 
n (%) 
Test HIV positive Yes 
No 
n 
24 (2) 
1169 (98) 
1193 (100) 
20 (2.8) 
693 (97.2) 
713 (100) 
4 (0.8) 
476 (99.2) 
480 (100) 
18 (3.5) 
491 (96.5) 
509 (100) 
6 (0.9) 
663 (99.1) 
669 (100) 
Test hepatitis B 
positive 
Yes 
No 
n 
104 (8.7) 
1089 (91.3) 
1193 (100) 
87 (12.2) 
626 (87.8) 
713 (100) 
17 (3.5) 
463 (96.5) 
480 (100) 
92 (18) 
417 (82) 
509 (100) 
11 (1.6) 
658 (98.4) 
669 (100) 
Test hepatitis C 
positive 
Yes 
No 
n 
442 (37) 
751 (63) 
1193 (100) 
363 (50.9) 
350 (49.1) 
713 (100) 
79 (16.5) 
401 (83.5) 
480 (100) 
408 (80.2) 
101 (19.8) 
509 (100) 
31 (4.6) 
638 (95.4) 
669 (100) 
Prison details       
Prison   Limerrick Female
Mountjoy Female 
Portlaoise 
Shelton Abbey 
St Patricks 
Mountjoy Training 
Cork 
Limerick Male 
Mountjoy 
Wheatfield 
n 
7 (0.6) 
50 (4.1) 
80 (6.6) 
38 (3.2) 
88 (7.3) 
77 (6.4) 
228 (18.9) 
135 (11.2) 
359 (29.8) 
143 (11.9) 
1205 (100) 
 
50 (7) 
 
 
88 (12.3) 
77 (10.7) 
 
 
359 (50.1) 
143 (19.9) 
717 (100) 
7 (1.4) 
 
80 (16.3) 
38 (7.8) 
 
 
228 (46.7) 
135 (27.7) 
 
 
488 (100) 
2 (0.4) 
32 (6.2) 
33 (6.4) 
10 (2) 
44 (8.6) 
36 (7) 
37 (7.2) 
18 (3.5) 
222 (43.2) 
80 (15.5) 
514 (100) 
5 (0.7) 
18 (2.7) 
47 (7) 
24 (3.6) 
43 (6.4) 
40 (5.9) 
187 (27.7) 
114 (16.9) 
136 (20.2) 
60 (8.9) 
675 (100) 
Risk  High
Medium 
n 
717 (59.5) 
488 (40.5) 
1205 (100) 
717 (100) 
 
 
 
488 (100) 
 
414 (80.5) 
100 (19.5) 
514 (100) 
297 (44.1) 
377 (55.9) 
674 (100) 
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Appendix 6 
Reported hepatitis B vaccine coverage in hepatitis B negative respondents only, in each prison 
Prison Completed 3 doses 
 
No. (%) 
Completed 1 or 2 
doses 
No. (%) 
Did not receive 
Vaccine 
No. (%) 
Total 
Portlaoise 35 (47.9) 24 (32.9) 14 (19.2) 73 
Mountjoy female 19 (43.2) 6 (13.6) 19 (43.2) 44 
Training Unit 27 (42.2) 21 (32.8) 16 (25) 64 
Mountjoy male 118 (41.1) 86 (30) 83 (28.9) 287 
Wheatfield 17 (16.3) 18 (17.3) 69 (66.3) 104 
St Patricks 10 (14.5) 6 (8.7) 53 (76.8) 69 
Limerick male 14 (13.7) 11 (10.9) 76 (75.2) 101 
Cork 20 (11.5) 10 (5.7) 144 (82.8) 174 
Shelton Abbey 1 (3.7) 5 (18.5) 21 (77.8) 27 
Limerick female 0 (0) 0 (0) 5 (100) 5 
Total 261 (27.5) 187 (19.7) 500 (52.8) 948 
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Appendix 7 
Table 7a – Logistic regression model to identify determinants of hepatitis B infection 
among the injecting drug using population 
 Total 
sample 
IDU 
509 
No. 
IDUs 
Hepatitis B 
negative 
416 
No. 
IDUs 
Hepatitis B 
positive 
93 
No. 
Prevalence of 
hepatitis B 
 
% 
Odds 
ratio 
95% CI p-value 
Age 
<30 
>30 
Missing 
 
382 
102 
25 
 
331 
64 
 
 
51 
38 
 
 
13.3 
37.2 
 
 
1 
4.1 
 
 
 
2.4-7.0 
 
 
 
<.0001 
 
Year since first 
injected 
3+ 
<3 years 
Missing 
 
 
85 
383 
41 
 
 
79 
301 
 
 
 
6 
82 
 
 
 
7.1 
19.4 
 
 
 
1 
.3.5 
 
 
 
 
.1-.9 
 
 
 
=.0548 
Ever treated for 
STI 
No 
Yes 
Missing 
 
 
412 
87 
10 
 
 
346 
62 
 
 
 
66 
25 
 
 
 
16.0 
28.7 
 
 
 
1 
2.1 
 
 
 
 
1.1-3.7 
 
 
 
 
=.0154 
 
Age x Time since 
1st inject 
 
 
 
 
 
 
 
 
0.8 
 
03-6.9 
 
=.8373 
 
Whole model x2 = 44.2 R2 = .10 p <.0001 
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Table 7b – Logistic regression model to identify determinants of hepatitis C infection 
among the injecting drug using population 
 Total 
sample 
IDU 
509 
No. 
IDUs 
Hepatitis C 
negative 
101 
No. 
IDUs 
Hepatitis C 
positive 
408 
No. 
Prevalence of 
hepatitis C 
 
% 
Odds 
ratio 
95% CI p-value 
Total amount of 
time spent in 
prison over the 
last 10 years 
<3 months 
3-11 months 
12-36 months 
>36 months 
Missing 
 
 
 
 
40 
49 
120 
296 
4 
 
 
 
 
21 
13 
25 
36 
 
 
 
 
 
19 
36 
97 
260 
 
 
 
 
 
47.5 
73.5 
80.8 
87.4 
 
 
 
 
 
1 
2.3 
2.4 
2.9 
 
 
 
 
 
 
0.9-7.1 
0.9-6.6 
1.1-7.2 
 
 
 
 
 
 
=.1347 
=.0748 
=.0288 
 
Year since first 
injected 
3+ 
<3 years 
Missing 
 
 
383 
85 
41 
 
 
 
56 
30 
 
 
327 
55 
 
 
85.4 
64.7 
 
 
1 
.34 
 
 
 
.2-.6 
 
 
 
=.0009 
Sharing needles 
In prison 
No 
Yes 
Missing 
 
 
145 
347 
17 
 
 
55 
33 
 
 
90 
314 
 
 
 
62.1 
90.5 
 
 
 
1 
2.9 
 
 
 
 
1.5-5.7 
 
 
 
 
=.0015 
 
No of times 
injected in the 
month prior to the 
survey 
0 
1-19 
20+ 
Missing 
 
 
 
 
221 
139 
74 
75 
 
 
 
 
44 
20 
7 
 
 
 
 
 
177 
119 
67 
 
 
 
 
 
80.1 
85.6 
90.5 
 
 
 
 
 
1 
1.1 
3.0 
 
 
 
 
 
 
0.5-2.1 
1.1-10.4 
 
 
 
 
 
 
=.8855 
=.0462 
 
Whole model x2 = 53.4 R2 = .15 p <.0001 
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Table 7c – Logistic regression model to identify determinants of HIV infection among 
the injecting drug using population 
 Total 
sample 
IDU 
509 
No. 
IDUs 
HIV 
negative 
491 
No. 
IDUs 
HIV 
positive 
18 
No. 
Prevalence 
of HIV 
 
 
% 
Odds 
ratio 
95% CI p-value 
Ever treated for 
STI 
No 
Yes 
Missing 
 
 
412 
87 
10 
 
 
401 
80 
 
 
 
1 
7 
 
 
 
2.7 
8 
 
 
 
1 
2.8 
 
 
 
 
0.9-8.1 
 
 
 
 
=.0565 
 
Use condom 
when have sex 
with women 
No 
Yes 
Missing 
 
 
 
311 
138 
60 
 
 
 
307 
126 
 
 
 
 
4 
12 
 
 
 
 
1.3 
8.7 
 
 
 
 
1 
7.1 
 
 
 
 
 
2.4-26 
 
 
 
 
 
=.0009 
 
Whole model x2 = 17.3 R2 = .13 p <.0002 
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Appendix 8 - Comments and  
observations made by 
the survey team 
All responses to Question 1 Informant 
Issues raised during conversations with prisoners: 
Several prisoners expressed that the doctors examination was very quick and usu-
ally not relevant to the condition for which they asked to be seen 
1
One or two said they had been denied drugs for illness which they had for 15-20 
years 
1
Some prisoners felt strongly about the lack of support services for prisoners wish-
ing to break a drug addition 
2
Many felt hopeless that nothing is or will be done regarding help for prisoners 
with big drug problems, but were not sure what needed to be done 
2
A number claimed they had tests done for hepatitis B, hepatitis C and HIV but 
were not informed of results 
2
Praise for some doctors, criticism for other – Mountjoy and Cork in particular 3
Confidentiality seems to be a problem 3
Some more articulate prisoners commented that mentally disturbed prisoners in ‘c’ 
wing of Mountjoy should be in hospital – having seen what they were taking about 
I agree 
3
Prisoners requested info on hepatitis B, hepatitis C – implications for their present 
and future health – didn’t know about it (and were positive) 
5
Confidentiality issues with guards knowing test results obtained through the prison 
medical service 
5
Requests for needle exchange services to be made available 5
Non-drug users worried about their exposure to infectious diseases 5
Vaccination schedules were often incomplete, the prisoner unaware of how many 
should be administered and some had been vaccinated on multiple separate occa-
sions – confusion and anxiety 
5
Female prisoners commented on inappropriateness of those suffering from psychi-
atric conditions in their midst 
6
The positive impact of the gym and education on health was mentioned 6
A specific question – can hepatitis and HIV be contracted through sharing a ciga-
rette or an apple? 
7
They discussed issues relating to inadequate primary care and GP facilities in 
prison. The need for a more comprehensive primary care service and better follow 
up was emphasised 
9
They discussed the need for methadone maintenance programmes 9
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One prisoner suggested that salivary testing should be used in prison rather than 
needles 
10
Another asked if he could have an HIV test done in prison and get the result 10
Limited access to health care, Lack of privacy, Assumption of malingering. As a 
result, delays in diagnosis, potentially damaging for the individual (and in the care 
of communicable disease – prisoners and staff and even relations) 
11
Many expressed the view that methadone should be more available in prison and 
that it should be possible to obtain maintenance methadone. Most felt that the de-
tox on offer was too rapid, at too low a dose (Mountjoy men) 
12
One prisoner expressed his concerns about sterilisation of dental equipment be-
tween patients – was concerned re potential for transmission of blood borne vi-
ruses 
13
Difficulty seeing a doctor when required 14
Liver biopsy appointments cancelled (in one case 5 times) because no prison staff 
available to accompany prisoner to hospital 
14
‘2 disprin’ when feelings of anxiety/depression expressed 14
The doctor here doesn’t give a shit (inmate in Mountjoy men) 14
No point complaining, no one cares anyhow 14
Women – shared razors! 16
Confidentiality – prisoners didn’t trust some medical officers (prison officers) 16
Food: Portlaoise best food, Limerick food awful and not enough! (this was said by 
quite a few prisoners, especially those who worked out in the gym) 
16
Concern re confidentiality of medical records 17
Poor access to prison doctor 17
Lack of confidence in prison doctor 17
Toilets blocked, dirty, concern expressed re infection risk 17
Some prisoners were concerned that razors were being shared 17
Several responders said they were not being given medication they get on the out-
side 
18
Methadone was not being given to responders who were on a programme on the 
outside 
18
The respondents were in general fairly negative about the health services provided 
in prisons. The medical officers in one of the prisons were severely criticised – it 
was stated that respondents always had to stand during medical consultations, and 
physical examinations were rarely, if ever conducted. 
19
Some respondents felt that the medical officers thought that the prisoners were 
subhuman and they did not merit medical attention. They treated them with ‘con-
tempt’. One prisoner said ‘oh the Drs in this prison never look us in the eye, they 
don’t listen to our problems.’ 
19
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Some prisoners mention that they would never have a test for any of the viral dis-
eases, as they would be interrogated rather than counselled, if they had a disease 
(infectious) they were treated with a very obvious non touch technique, this disease 
seemed more contemptuous than their crime. People with HIV, hepatitis and TB 
reported to be treated very poorly by prison officers, as there was an abnormal 
fear of contracting the disease. One prisoner was advised not to have testing, as 
he would be incapable of reducing his risk factors. 
19
Confidentiality was not respected according to prisoners. The governor, POs and 
other inmates often knew infected prisoners through leakage of info. 
19
Some of the prisoners mentioned that they would never have a test for any of the 
diseases, as they did not want to deal with the consequences. Hepatitis vaccine 
was the one health intervention that could be accessed. However Hepatitis B posi-
tive individuals were also given the vaccine, although prisoners with short sen-
tences were refused vaccines, as they could not complete the 6-month course. One 
prisoner said ‘the vaccine sure that is the only part of the H/S that functions here’. 
19
Many prisoners felt that research surveys were a good thing as it recorded prob-
lems and may be used to improve the situation. 
19
One prisoner said that the only drugs available were sleeping tablets and aspirin 19
A few prisoners mentioned that there were a few good doctors attached to special-
ised units with the prison. One prisoner said Dr. X was a very good man ‘he 
speaks to us and listens to our problems’, ‘he treats us like humans’. Interestingly 
many complaints were about the Drs rather than the POs. 
19
Many comments were negative as they were unsolicited and those with complaints 
took the opportunity to voice them. 
19
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All responses to Question 2 Informant 
Observations about the prison health care service: 
Although tests for hepatitis B, hepatitis C and HIV seemed readily available in 
the prisons there seemed to be no structured support infrastructure for infected 
prisoners 
2
Under-resourced 3
Lack of confidentiality – medical orderlies are prison officers 3
Vagueness about accountability 3
More explicit policies would help 3
To a certain extent the present system seems to suit in that visits to hospital out-
patients are welcomed by prisoners (day out) and prison officers (overtime, day 
out) 
3
The prisoners seem to identify the health service they receive with the guards & 
prison regime rather than something separate from them – this may inhibit their 
accessing of the system except in acute circumstance 
5
There is no consistency of prevention services and treatment between prisons, 
and the quality of care can be a matter of where you are and which doctor is 
looking after you. The prisoners move between prisons frequently – by their ac-
count 
5
Some of the prisoners seemed to lack information. Are there health informa-
tion/promotion programmes in place? 
7
Are interested individuals among the prisoner population trained to deliver 
health promotion to their fellow prisoners? 
7
The happiest seeming person I met among the prisoners on the two occasions 
when I helped out was a young prisoner who ran exercise classes. And the pris-
oner seemed to have a good sense of their own worth which probably contributed 
to their general well-being. (Wording altered slightly to maintain confidentiality) 
7
Need more organised comprehensive primary care services and psychiatric ser-
vices 
9
Need for methadone maintenance programmes +/- needle exchange 9
The need for a more organised hepatitis B vaccination programme 9
Many of the prisoners were unaware of their HIV/hepatitis status and were anx-
ious to get the results of the testing which was carried out as part of this survey. 
This issue could be addressed by the prison health care service in the future 
10
In Portlaoise the prisoners, in general, seemed quite happy with their circum-
stances 
10
Prisoners forgo the right to freedom in prison – they should not have any worse a 
medical system than any non-incarcerated person should expect on the outside 
11
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Need for one medical director on each prison who would be interested in screen-
ing for TB, blood borne viruses etc. on entrance to prison system – should not 
only be based on symptoms and GP issues 
13
Appears to run on an ad-hoc basis. 14
Positions held by semi-retired, not so dynamic/innovative medics. 14
Definite need for greater psychological services in Mountjoy. I saw on 2 occa-
sions 3 prisoners in one cell, 2 kept the suicidal one ‘company’/Hardly the mod-
ern treatment, or have I missed something? 
14
Prisoners particularly unhappy about health care service in Limerick and 
Mountjoy. ‘Treated and spoken to like animals’ 
16
Never given proper examination (except in Training Unit) 16
One prisoner (Limerick) was refused x–ray for probable broken arm 16
Cork – good psychiatric services – setting up cognitive skills course for ordinary 
prisoners (as well as sex offenders) 
16
Many responders said they were unhappy with the provision of health care given 
to them i.e. length of time it took to see a doctor – very little time given to them 
by doctor. Many prisoners who were started on hepatitis B vaccination pro-
gramme did not know what they were getting. 
18
I think it would be unfair to make any detailed comments about the health ser-
vices although there are a few issues which would warrant valid investigation 
Health services as a right or entitlement 
Medical orderlies used as health professionals 
Medical orderlies divulging confidential info to other POs 
Medical orderlies providing drug treatment through metal bars 
Medical orderlies putting prisoners requests on the long finger 
Prison officers paranoia about contracting infectious disease 
The infection control methods within the prison 
Treatment of ‘drug abuse in the same manner as alcohol abuse 
The use of benzos rather than methadone to stabilise/satisfy drug addicts 
Smoking policy in the prison seems contrary to current legislation 
The fact that medical doctors need to order ‘basic needs’ such as diets, clothes 
and toiletries  
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